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ABSTRACT
It has been proposed that rapid forgetting of recently
learned visual information is a consequence of medial temporal-lobe
pathology. This hypothesis was tested in patients with Alz-
heimer's disease (AD), who have marked degeneration in medial
temporal-lobe structures.
Picture recognition was studied in 20 patients with AD
and in 20 control subjects, using a procedure that matched these
groups for initial performance. The groups did not differ signi-
ficantly in overall forgetting, although 10 patients displayed
improved recognition performance 72 hours after learning relative
to their performance 24 hours after learning. These same patients
were impaired relative to other AD patients on a test of attentional
focusing, as revealed by posthoc analyses.
A subsequent predictive experiment involving 20 new patients
with AD confirmed the initial findings: A subset of patients
displayed a rebound in recognition performance 72 hours after
learning. This subgroup of AD patients also displayed impairments
in attentional focusing. It was postulated that these behavioral
deficits were the result of locus coeruleus degeneration, which
has been reported at autopsy in some patients with AD.
This hypothesis was tested in a third experiment, which
examined the association between deficits in selective attention
and reduced levels of MHPG, the major metabolite of norepinephrine,
in the cerebrospinal fluid of 22 AD patients. A significant
relation between deficits in selective attention and reduced
levels of the metabolite was noted when the data were grouped
according to gender.
In a fourth experiment, the picture-recognition and attentional
focusing tests were used to classify patients according to pre-
sumptive locus coeruleus pathology. The two groups of patients
thus identified were administered clonidine, a noradrenergic
agonist. The two groups responded differentially to clonidine,
suggesting that behavioral tests can identify a subgroup of
patients with abnormal noradrenergic neurotransmission, possibly
reflecting marked degeneration in the locus coeruleus.
Thesis Supervisor: Professor Suzanne Corkin
Title: Associate Professor
Department of Brain and Cognitive Sciences
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INTRODUCTION
It is estimated that 2.5 million Americans have Alzheimer 's
disease (AD), a neurological disorder characterized by progres-
sive dementia (Blessed, Tomlinson, and Roth, 1968). The
essential feature of dementia is a loss of intellectual
abilities in a number of realms to the extent that the indi-
vidual's social or occupational functioning is impaired
(D.S.M. III, 1984). Patients with AD display numerous cognitive
deficits, including loss of recent memory, disorientation,
aphasia, and constructional apraxia (Corkin, 1981). Clinically,
a diagnosis of AD is made when other systemic and brain
diseases can be excluded as the cause of dementia (McKahn
et al., 1984; Khachaturian, 1985).
The memory impairments associated with AD are believed
to be due at least in part to a loss of cholinergic neurons
originating in the medial septum, diagonal band of Broca,
and nucleus basalis of Meynert, which project to the amygdala,
hippocampus, cerebral cortex, and olfactory bulb (Whitehouse
et al., 1981). It has been suggested that agents that increase
the release of acetylcholine (ACh) from cholinergic neurons
in the basal forebrain could ameliorate the memory loss
(Wurtman et al., 1981). The cholinergic hypothesis, however,
has not been validated by clinical trials of choline, lecithin,
or physostigmine in patients with AD (Corkin, 1981).
8
Recent autopsy studies note the existence of a subgroup
of patients with severe locus coeruleus (LC) degeneration
(Bondareff, Mountjoy, and Roth, 1982; Iversen et al., 1983).
Both studies showed that female patients with AD are more
likely to display severe LC degeneration than male patients.
The purpose of the following experiments was to identify
a subgroup of patients with LC pathology using neuropsychological
tests.
The experiments addressed four questions: (1) Is there
an interaction between recognition memory and selective
attention; (2) Are the LC and its major neurotransmitter
norepinephrine (NE) involved in selective attention; (3)
Can neuropsychological tests identify patients with LC pathology;
(4) Are female patients with AD more likely than male patients
to display deficits in selective attention, and are these
deficits secondary to LC pathology?
The results of these experiments have broader implications
for AD research. The identification of subgroups of patients
related to neuropathology will improve the physician's ability
to treat individual patients. In addition, studies of subgroups
of patients are likely to provide insight into the etiology
of AD. Other neurological disorders are also associated
with LC degeneration (e.g., Parkinson's disease). The results
of these experiments provide a framework for studies of
selective attention in other types of patients with LC degen-
eration.
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These experiments examine the role that NE plays in
recognition memory and selective attention. Because there
is a circadian rhythm of NE release in the human (Major,
Lerner, and Ziegler, 1984), the experiments reported here
have ramifications for studies of human performance. Because
brain NE concentrations have been shown to decrease with
age (Carlsson, Nyberg, and Winblad, 1984; Robinson et al.,
1977), and age-related reductions in LC cell volume have
been reported (Mann and Yates, 1979), these experiments
also have an impact on studies of normal aging.
SPECIFIC AIMS
The purpose of these experiments was to (1) investigate
the psychological basis of the rebound in recognition performance
observed in the first experiment by replicating and extending
the findings in a second group of patients; (2) test the
hypothesis that the LC is involved in the rebound phenomenon
by examining the correlation between test performance and
levels of metabolites in the cerebrospinal fluid (CSF) of
patients with AD; (3) test the hypothesis that noradrenergic
neurons are involved in human selective attention by admini-
stering the noradrenergic agonist, clonidine, to patients
with AD; and (4) assess the adequacy of hypotheses developed
from animal research in explaining cognitive deficits related
to LC pathology in patients with AD. The following experiments
were thus designed to test the hypothesis that neuropsychological
tests can identify a subgroup of patients with AD who have
LC pathology.
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BACKGROUND
Clinical Features of Alzheimer's Disease
AD accounts for approximately 50% of the patients diagnosed
as demented and is more prevalent among women than men (McKahn
et al., 1984). In the past, the term Alzheimer's disease
referred to dementia in patients under the age of 65 (so-called
presenile dementia); the term senile dementia was applied
to patients over the age of 65 (Katzman, Terry, and Bick,
1978). At present, there is no clear rationale for this
distinction, and I will use the term AD to refer to both
senile and presenile forms of the disease.
Clinically, a diagnosis of probable AD is made when
there is insidious onset and progression of dementia, and
no other systemic, brain, or psychiatric disease can be
found to account for the disorder (McKahnn et al., 1984).
AD is characterized by marked cognitive deficits, including
problems in learning and memory, orientation, perception,
word-finding, fluency, and praxis. The experiments that
comprise this disseration focus on deficits in memory, attention,
and word-finding as displayed by patients with AD, and neuro-
chemical correlates of impaired cognition in these realms.
AD advances in an uneven manner, with the initial symptom
usually a loss of recent memory, followed by difficulties
with language and constructional tasks (Corkin, 1981).
Personality changes and behavioral abnormalities are common
12
features of mild to moderate AD. Other symptoms which are
observed in the late stages of AD include poor appetite,
unsteady gait, sleep disturbance, and agitation. Most patients'
social behavior remains appropriate until the late stages
of the disease (Corkin, 1981).
In AD, the snout and grasp reflexes have been correlated
with impaired performance on cognitive tests, but not accentuated
jaw-jerk, glabellar reflex, paratonia, suck, root, or palmomental
reflexes (Tweedy et al., 1982). Generally, these signs
correlate more strongly with CT evidence of ventricular
dilatation than with cortical atrophy and cannot be considered
clinical markers of dementia (Tweedy et al., 1982). It
has been noted that the scores on the Digit Symbol subtest
of the Wechsler Adult Intelligence Scale (WAIS) and an aphasia
battery correctly predicted the stage of dementia 1 year
later in a group of mildly demented AD patients over the
age of 65 (Berg et al., 1984).
Age at onset has been used to delineate subgroups of
patients with AD. Early onset dementia has been associated
with more severe aphasia (Seltzer and Sherwin, 1983) and
with more severe neurochemical and pathologic features (Bonda-
reff, 1983). Ties between early onset dementia and specific
impairments in recognition memory and selective attention
will be examined in the experiments that comprise this disser-
tation. Associations between early onset, aphasia, and
familial AD have been emphasized in previous studies (Folstein
13
and Breitner, 1981; Breitner and Folstein, 1984; Mohs,
Silverman, Greenwald, and Davis, 1984).
AD is more prevalent among women than men (McKahn et
al., 1984), but it is uncertain whether this finding is
an artifact due to the longer life expectancy of women.
Recent autopsy reports suggest that women with early-onset
AD are more likely to display severe LC degeneration than
men (Bondareff et al., 1982; Iversen et al., 1983). The
number of cases examined in these studies is relatively
small, and the significance of the observation remains unclear.
The association between gender and LC degeneration will
be examined in the following experiments.
Recent behavioral studies provide further evidence
for the existence of subgroups of patients with AD. Chui,
Teng, Henderson, and Moy (1985) evaluated clinical subtypes
of AD by comparing age at onset, family history, aphasia,
and motor disorder in a series of 146 patients. These inves-
tigators concluded that early onset was significantly associated
with more prevalent and more severe language disorder.
Myoclonus and noniatrogenic extrapyramidal disorder were
associated with greater severity of dementia, independent
of duration of illness. These results provide behavioral
evidence of a subgroup of patients with AD, a subgroup chara-
cterized by a movement disorder and greater severity of
dementia. Mayeux, Stern, and Spanton (1985) confirmed these
observations in a series of 121 patients with AD, noting
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that patients with extrapyramidal signs or myoclonus had
greater intellectual decline and functional impairment in
daily activities. Among patients studied longer than 4
years, Mayeux et al. concluded that there were four groups:
benign, myoclonic, extrapyramidal, and typical. The authors
suggested that dementia of the Alzheimer type is hetero-
genous, and that certain clinical manifestations may be
useful in predicting outcome."
Chui et al. (1985) also noted that 45% of all probands
had a family history of dementia. There was a trend in
this study that suggested a relationship between aphasia
and family history. Furthermore, there was a near significant
trend for patients who could not write a sentence during
the course of a mental status examination to have a higher
prevalence of familial cases of dementia than those who
were not agraphic. These observations support the findings
of Breitner and Folstein (1984), who reported that, in older
women who were demented for at least 4 years, an inability
to write a sentence was associated with a higher family
incidence of dementia. These investigators proposed that
agraphia or aphasia identifies a subgroup of patients with
AD that is transmitted in an autosomal dominant fashion
with incomplete and delayed penetrance. It is presumed
that the identification of patients with a family history
of dementia will delineate a relatively homogenous subgroup
of patients with AD prior to autopsy. Unfortunately, it
15
is difficult to establish a family history of AD retrospectively.
The literature on the clinical features of AD suggests
that age at onset, family history, and possibly gender provide
a way to categorize patients. Gender and age at onset are
the most likely variables to yield a categorization scheme
for AD in the near future.
The results of studies by Chui et al. (1985) and Mayeux,
Stern, and Spanton (1985) suggest that behavioral measures
are also useful in classifying patients with AD. It is
assumed that a subgroup of patients displaying specific
behavioral deficits are likely to share a pattern of neuro-
pathology as well. Therefore, the identification of distinct
subgroups of patients would provide the practicing physician
with the means to tailor pharmacological treatments to individual
patients.
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Neuropathology of Alzheimer's Disease
The neuropathology observed in AD includes senile plaques,
neurofibrillary tangles, granulovacuolar degeneration, cerebral
atrophy, and subcortical nuclear degeneration (Blackwood
and Corsellis, 1976). These topics are addressed in the
following paragraphs.
The neuropathologic hallmarks of AD include senile
plaques (extracellular clusters of abnormal cell processes
and amyloid) and neurofibrillary tangles (intracellular
paired helical fragments), which are particularly abundant
in temporal-lobe structures, including the hippocampus (White-
house et al., 1981; Hyman et al., 1984).
Progressive deterioration of dendrites in cortical
and hippocampal pyramidal cells, and granulovacuolar degeneration
in the hippocampus are also consistent neuropathological
features of AD. Medial temporal-lobe structures, particularly
the hippocampus, are known to be involved in disorders of
human memory, as epitomized by the famous neurological patient
H.M. H.M. underwent a bilateral medial temporal-lobe resection
for the relief of intractable epilepsy and has been the
subject of many experiments (Milner, Corkin, and Teuber,
1968; Corkin, 1984).
The pathological changes in the brains of AD patients
also include diffuse cortical degeneration, especially severe
in the temporal and parietal lobes (Blackwood and Corsellis,
17
1976; Brody, 1978). The posterior cingulate gyrus, amygdala,
hypothalamus, hippocampus, and certain midbrain structures
are also affected in AD (Arai, Kosaka, and Iizuka, 1985).
In regard to subcortical nuclear degeneration, Whitehouse
et al., (1981) reported that patients with AD had significantly
fewer cholinergic neurons in the nucleus basalis of Meynert
than did age-matched control subjects. Recently, it was
suggested that when the cholinergic cell count in the basal
forebrain drops below about 100,00 cells, the level of cortical
choline acetyl-transferase (CAT) may be so low that clinical
dementia appears (McGeer et al., 1984). Other investigators
noted significant decreases in the level of CAT, the rate
limiting enzyme in the formation of ACh, in the brains of
patients with AD (Davies and Maloney, 1976). The decrease
in CAT activity in AD is much greater than occurs in elderly
subjects who are not demented. Furthermore, the decrease
in CAT activity correlates with the regional distribution
and number of senile plaques and neurofibrillary tangles
in patients with AD.
The basal forebrain is a primary source of cholinergic
neurons that project widely to cortical targets (Whitehouse
et al., 1981). It was hypothesized that the memory impairments
associated with AD were due at least in part to degeneration
of neurons in the nucleus basalis of Meynert, diagnonal
band of Broca, and medial septal area, structures that project
to the amygdala and hippocampus as well as the cerebral
18
cortex (Whitehouse et al., 1981). It was assumed, therefore,
that the memory impairments seen in AD were due to a loss
of cholinergic neurons in structures believed to be important
for learning and memory. Recent attempts to treat the memory
impairments associated with AD using cholinergic agents
have been disappointing, however. This lack of support
for the cholinergic hypothesis might mean that one or more
non-cholinergic neurotransmitters are involved in AD (Corkin,
1981).
Reports of subcortical nuclear degeneration in AD suggest
that the LC, raphe nuclei, and substantia nigra are also
affected and that neurotransmitters other than ACh may be
involved in the pathogenesis of AD; evidence exists of
chemoanatomical heterogeneity in the neuropathology of AD
(Perry et al., 1981; Bondareff et al., 1982; Mann, Yates,
and Hawkes, 1982; Iversen et al., 1983; Arai et al., 1985).
Bowen et al. (1983) concluded that biochemical markers of
serotonergic synapses are significantly reduced in neocortical
brain tissue from patients with AD. For samples from the
temporal lobe, the reduction in markers of postsynaptic
serotonergic receptors was a feature only of neocortical
samples taken from the brains of patients with early onset
AD (Bowen et al., 1983). These same authors concluded that
CAT activity was significantly reduced in all groups of
Alzheimer specimens, irrespective of age. Bowen et al. (1983)
suggested that in AD there is loss of neuronal structures
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other than those associated with cholinergic perikarya in
the basal forebrain. This suggestion is supported by the
results of a study by Arai et al. (1985). These investi-
gators noted significant degeneration in midbrain raphe
neurons in patients with AD, as well as elevated numbers
of neurofibrillary tangles in this region.
A number of investigators have reported significant
LC degeneration in the brains of patients with AD (Perry
et al., 1981; Bondareff et al., 1982; Iversen et al.,
1983; Arai et al., 1985). Bondareff et al. (1982) reported
significant LC degeneration in 12 of 20 cases of AD studied
at autopsy. The subgroup of AD patients with significant
LC degeneration included more women than men and was charac-
terized by a high dementia score and a relatively young
age at death. Iversen et al. (1983) studied 6 cases of
AD and reported that LC neuron loss varied considerably,
with some cases showing significant LC degeneration. Mann
et al. (1982) reported that in 8 of 19 AD cases, there was
"gross underpigmentation' in the LC.
The subcortical nuclear degeneration observed in the
brains of patients suggest that the cholinergic, noradrenergic,
and, to a lesser extent, the serotonergic neurotransmitter
systems are affected in AD. Due to the disappointing results
of attempts to treat the memory impairments associated with
AD using choinergic agents, recent reports of severe LC
degeneration in a subgroup of patients with AD, and the
20
results of animal experiments which suggest that NE is involved
in learning and memory (see the section on animal behavior),
the experiments that comprise this dissertation focus on
the noradrenergic system and its role in AD.
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Neurochemistry of Alzheimer's Disease
The neurochemical changes that take place in the brains
of patients with AD are presumed to be the result of alterations
in the expression of functional molecules in specific clusters
of neurons, as described in the previous section. Therefore,
the following discussion on the neurochemistry of AD will
begin with a review of abnormal proteins found in the brains
of patients with AD and subsequent sections will be organized
according to the neurotransmitters involved.
Abnormal Proteins
Amyloid deposition in the walls of small intracortical
blood vessels (congophilic angiopathy) occur less frequently
in cortex from patients with AD than do neuritic plaques
and neurofibrillary tangles (Blackwood and Corsellis, 1976).
The term amyloid refers to tissue deposits of proteinaceous
fibrils, which vary widely in their protein compositions.
Amyloid deposits have a common molecular conformation, referred
to as a beta-pleated sheet configuration. Amyloid fibrils
are composed of immunoglobulin light chains or their proteolytic
fragments or both. Amyoid is an end-stage product of a
variety of disease processes. All amyloid is characterized
by a high degree of insolubility in laboratory solvents
and resistance to proteolytic digestion (Selkoe, 1982).
The nature of amyloidosis observed in the human brain as
22
neuritic plaque cores and congophilic angiopathy, therefore,
is not well understood and awaits purification and chemical
analyses (Selkoe, 1982).
Lipofuscin deposition in neurons and glia has been
linked to the aging process. Lipofuscin granules are highly
heterogenous and include lipids, proteins, cations, and
acid-resistant residues (Corsellis and Blackwood, 1976).
It is of interest that lipofuscin granules copurify with
neurofibrillary tangles and the amyloid core of senile plaques
in the detergent-insoluble fraction of cortex from patients
with AD (Selkoe, 1982).
Recently, Wolozin, Pruchnicki, Dickson, and Davies
(1986) prepared monoclonal antibodies against brain tissue
from patients with AD in order to study abnormal proteins
that may be present in AD. The investigators isolated an
abnormal protein called Alz-50 from the brains of patients
with AD. This protein is found in neurons involved in the
formation of neuritic plaques and neurofibrillary tangles.
Alz-50 immunoreactivity appears to precede the deposition
of neurofibrils to form tangles. Thus Alz-50 may recognize
a precursor to tangle formation. The function and identity
of the proteins recognized by Alz-50 remains to be elucidated,
however. The results of this study raise the possibility
that a diagnosis of AD can be confirmed through the use
of monoclonal antibodies to Alz-50 and that blocking the
synthesis of Alz-50 may be useful in the treatment of patients
23
with AD.
Acetylcholine
Bowen, Smith, White, and Davison (1976) presented the
first evidence that a specific neurotransmitter deficit
occurred in AD. These authors reported that the activity
of choline acetyl-transferase (CAT), the enzyme that acetylates
choline to form ACh, was reduced in the brains of patients
with AD. Other investigators quickly confirmed these results
(Davies and Maloney, 1976), and noted that muscarinic receptor
binding was normal in AD (Perry, Perry, Blessed, and Tomlinson,
1976; White et al., 1977). Acetyl cholinesterase (AChE),
the enzyme that degrades ACh, is significantly reduced in
the brains of patients with AD (Terry and Davies, 1980).
The decrease in CAT activity observed in AD correlates with
the regional distribution and number of senile plaques and
neurofibrillary tangles, as well as mental status (Blessed
et al., 1968). These correlations suggested that decreased
CAT activity may be important in the clinical manifestation
of AD and motivated a number of attempts at therapeutic
intervention (Growdon and Corkin, 1980), which to date have
been disappointing (Corkin, 1981).
Norepinephrine
Decreased brain levels of NE apparently occur as part
of the aging process (McGeer and McGeer, 1976). The metabolism
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of NE has been reported to be affected by AD as well (Adolfsson
et al., 1978; Nyberg et al. 1984). Reports that certain
patients with cholinergic deficits also show reductions
in NE have been discounted on the grounds that the clinical
diagnoses of AD were not checked against autopsy findings
(Corkin, 1981). However, the apparent ineffectiveness of
lecithin precursor treatment in AD may mean that one or
more non-cholinergic neurotransmitters are involved in AD
(Corkin, 1981). Moreover, recent neuropathological evidence
demonstrates the existence of a subgroup of patients with
severe LC degeneration (Bondareff et al., 1982; Iversen
et al., 1983), as discussed in the previous section.
Reports of LC degeneration are supported by the existence
of significant decreases of NE and its metabolites in the
brains of patients with AD (Arai et al., 1985; Winblad
et al., 1980) because the LC is the major source of cortical
NE. A noradrenergic deficit in AD has been found by almost
all investigators who have studied this possibility (Nyberg,
1984). These studies are complicated by the fact that the
superior cervical ganglion, a peripheral nervous system
structure, has extensive noradrenergic projections to cerebral
arteries. It is difficult, therefore, to claim that reductions
in brain NE are due solely to LC degeneration. Regardless,
it is likely that the noradrenergic as well as the cholinergic
neurotransmitter system is affected in AD.
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Dopamine
Evidence for a reduction in levels of dopamine (DA)
in the brains of patients with AD is less conclusive than
that for involvement of the cholinergic or noradrenergic
systems (Nyberg, 1984). Thus, there is evidence supporting
(Adolfsson et al., 1979; Carlsson et al., 1980; Mann et
al., 1980) and refuting (Yates et al., 1979; Yates et al.,
1983) a dopaminergic loss. Data concerning the DA metabolite
homovanillic acid (HVA) in both brain and CSF are also conflict-
ing (Nyberg, 1984).
Serotonin
Data concerning the state of the serotonergic system
in AD are relatively sparse (Nyberg, 1984). Most studies
to date, however, agree that there is a loss of serotonergic
activity in the brains of patients with AD. Reduced nucleolar
volume in the raphe area (Mann and Yates, 1983) and the
presence of tangles in these nuclei (Ishii, 1966) have been
observed. Serotonin concentrations in the brains of patients
with AD have been reported to be reduced (Adolfsson et al.,
1979; Carlsson et al., 1980). Bowen et al. (1983) reported
that when AD samples were subdivided according to age, there
was a significant reduction in serotonin binding, but not
DA binding, that was a feature of autopsy samples from younger
patients only. In contrast, presynaptic cholinergic activity
was reduced in all groups of AD samples in this study.
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Bowen et al.'s (1983) results must be regarded carefully,
however, because the exact relationship between neurotransmitter
synthesis and receptor binding is unclear as of yet; decreases
in neurotransmitter synthesis do not necessarily imply decreases
in receptor binding. In fact, reductions in brain levels
of NE have been shown to result in increased numbers of
noradrenergic receptors (U'Prichard, Greenberg, Sheehan,
and Snyder, 1977; Pandey and Davis, 1981; Janowsky et
al., 1982), which has been termed up-regulation. This form
of regulation may also exist for other neurotransmitter
systems.
Somatostatin
Another neurotransmitter that has been investigated
in patients with AD is somatostatin. A recent study by
Beal, Growdon, Mazurek, McEntee, and Martin (1984) demonstrated
reduced CSF concentrations of somatostatin-like immunoreactivity
(SLI) in AD. The reduced CSF concentrations of SLI are
consistent with known reductions of SLI in the cerebral
cortex of patients with AD (Rossor, Emson, Iversen, Mountjoy,
and Roth, 1984). The results of Beal et al.'s (1984) study
suggest that decrements in CSF SLI concentration lack diagnostic
specificity and must be considered in combination with other
neurochemical markers.
The studies described above suggest that levels of
biogenic amines may be reduced in the brains of patients
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with AD. It should be noted, however, that measures of
neurotransmitters in the brain can be affected by a variety
of factors, including age, sex, and the amount of time elapsed
since death. Only reports of reduced brain levels of ACh,
NE, and to a lesser extent serotonin, are supported by studies
of the neuropathology characteristic of AD, as described
in the previous section. Because recent attempts to treat
patients with AD using cholinergic agents have been disappoint-
ing and reports of raphe neuropathology in AD are relatively
sparse, the following experiments center on the behavioral
deficits presumed to be related to LC degeneration.
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Overview of Locus Coeruleus Neuroanatomy
Given the reports of LC neuropathology in patients
with AD, knowledge of the organization of this nucleus is
likely to provide clues to its role in cognition.
The cell bodies and efferent connections of the LC
have been studied since the 1960s using the Falck-Hillarp
fluorescent histochemical method, which allows the visualization
of catecholamine-containing neurons (Swanson and Hartman,
1975; Moore and Bloom, 1979). The LC is a source of both
dopaminergic and noradrenergic fibers, which cannot be reliably
differentiated using the Falck-Hillarp method alone (Foote,
Aston-Jones, and Bloom, 1980). The development of immunohisto-
chemical methods in the past decade has provided the means
to identify catecholamine-containing neurons through antibodies
directed against tyrosine hydroxylase. Immunohistochemical
methods can also be used to distinguish NE-containing neurons
through antibodies directed against dopamine-beta-hydoxylase,
an enzyme specific for these cells.
In the rat, the ascending fibers of the LC that enter
the medial forebrain bundle give rise to several distinct
groups of fibers (Swanson and Hartman, 1975; Moore and
Bloom, 1979). The largest group is made up of fibers that
leave the medial forebrain bundle laterally along its course
to enter the ansa peduncularis/ventral amygdaloid bundle.
Another group enters the mammillothalamic tract to ascend
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to anterior thalamic nuclei. At the caudal septum, fibers
in the medial forebrain bundle divide into five major groups.
One group ascends medially into the diagonal band of Broca
to innervate the septum and enter the fornix. A second
group enters the stria medullaris caudally and continues
to the habenular nuclei. A third group enters the stria
terminalis and eventually reaches the amygdaloid complex.
A fourth group continues in the medial forebrain bundle
and projects to the basal telencephalon. A fifth group
of fibers projects around the genu of the corpus callosum
and then continues caudally in the cingulum (Moore and Bloom,
1979).
Two other groups of fibers leave the LC. One ascends
via the superior cerebellar peduncle to innervate the cere-
bellum. Another descends in the central tegmental bundle
to enter the ventral portion of the lateral column of the
spinal cord (Moore and Bloom, 1979).
The septal area of the rat is known to receive a rich
projection of axons arising from the LC and nuclei in the
caudal brainstem. LC axons distribute in the septal area
to the hippocampal rudiment, the nucleus of the diagonal
band, the interstitial nucleus of the stria terminalis,
the medial septal nucleus, the lateral septal nucleus, and
the nucleus septofimbrialis (Moore, part 1, 1978).
Moore (part 2, 1978) used histofluorescence and a tyrosine
hydroxylase assay to study the efferent connections of the
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LC. Moore noted that the amygdala and entorhinal cortex
have a moderate catecholamine content, arising primarily
from the LC. Later studies have confirmed that the LC is
the major source of NE innervation of the telencephalon
(Grzanna and Molliver, 1980; Foote, Bloom, and Aston-Jones,
1980) through the use of the NE-specific dopamine-beta-hydroxy-
lase immunocytochemistry. It has recently been shown that
populations of LC neurons contain the peptides neuropeptide
Y and galanin, in addition to NE (Holets, Hokfelt, Terenius,
and Goldstein, 1984). These investigators concluded that
99% of LC neurons contain tyrosine hydroxylase. Of the
population of neurons containing tyrosine hydroxylase, 25%
contained neuropeptide Y and 83% contained galanin. Holets
et al. (1985) suggested that there are functional divisions
in the LC based on the peptide contained within the neurons
and their afferent projections.
Shipley, Halloran, and De La Torre (1985) used a horse-
radish-peroxidase retrograde tracing method in rats and
reported that at least 40% of all LC neurons project to
the olfactory bulb. Shipley et al. (1985) noted that the
LC projection to the olfactory bulb is nearly 10 times greater
than to any other part of the cerebral cortex. These data
suggest that patients with LC degeneration may display deficits
in olfaction.
Other investigators found that the distribution of
LC neurons and their fibers in a pygmy primate was similar
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to that observed in the rat (Jacobwitz and MacLean, 1978).
Jacobwitz and MacLean (1978) used the Falck-Hillarp method
and noted that the findings "conform in essential details
to what has been described in rodents.' Later studies of
the primate LC (Schofield and Everitt, 1981a; Schofield
and Everitt, 1981b) have been consistent with the previously
described reports in rodents.
Morrison, Molliver, Grzanna, and Coyle (1981) studied
the trajectory of the coeruleo-cortical projection in the
rat using histofluorescence as well as immunohistochemistry.
The immunohistochemical procedure made use of an antibody
directed against rat dopamine-beta-hydroxylase, which is
specific to noradrenergic neurons. Morrison et al. (1981)
concluded that the tangential, intracortical trajectory
of the noradrenergic fibers would confer upon the coeruleo-
cortical system the capacity to modulate neuronal activity
simultaneously through a vast expanse of cortex." The ultra-
structure of LC neurons suggest that NE may function to
modulate ongoing activity over widely dispersed neuronal
populations for relatively long periods of time rather than
exerting a direct one-to-one influence on individual postsynaptic
cells (Dismukes, 1977).
The LC projects to virtually all components of the
amygdaloid complex, although these projections are preferential
to the central nucleus of the amygdala (Moore and Bloom,
1979). The hippocampus receives NE projections exclusively
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from the LC (Moore and Bloom, 1979). The amygdala and hippo-
campus are known to be involved in human memory disorders,
as epitomized by the patient H.M. For other cortical areas,
it is estimated that each cubic millimeter of cerebral cortex
contains approximately 96,000 LC NE terminals (Lapierre
et al., 1973). Each rat LC neuron is believed to have an
axon at least 30 cm in length, with over 100,000 terminals
(Moore and Bloom, 1979).
The LC has rich projections to the amygdala, hippocampus,
and basal forebrain. These areas are the primary sites
of neuropathology in AD (Whitehouse et al., 1981). A monosyn-
aptic pathway from the LC to the hippocampus has been described
(Segal and Bloom, 1974). Cytochemical, pharmacological,
and iontophoretic data indicate that this pathway utilizes
NE to inhibit hippocampal pyramidal cells. In addition,
there is a striking correlation between the reinforcing
properties of LC stimulation and the inhibitory effects
in the hippocampus (Segal and Bloom, 1976). Based on physio-
logical and behavioral data, Segal and Bloom (1976) concluded
that the LC and its projections to the hippocampus are involved
in selective attention. Detailed electrophysiological studies
of the basis of NE-induced depression suggest that NE differ-
entially suppresses background activity induced by afferent
input with a resulting enhancement of the evoked excitation
(Quartermain, 1983; Segal and Bloom, 1976). NE appears
to increase signal-to-noise ratio rather than uniformly
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inhibiting activation (Segal and Bloom, 1976). It has been
suggested that NE could promote learning and facilitate
retrieval by suppressing irrelevant background information,
while simultaneously amplifying inputs from significant
environmental stimuli (Segal and Bloom, 1976).
Other investigators have proposed that selective attention
is the result of a neural mechanism that serves a screening
function similar to the one identified by Segal and Bloom
in their electrophysiological data (Rabbitt, 1965; Mason
and Iversen, 1978a; Mesulam and Geschwind, 1978; Quartermain,
1983; Foote, Bloom, and Aston-Jones, 1983; Mair and McEntee,
1983; Posner, Walker, Friedrich, and Rafal, 1984). A number
of these studies implicate NE in the neural processes that
filter out irrelevant stimuli (Mason and Iversen, 1978a;
Quartermain, 1983; Foote, Bloom, and Aston-Jones, 1983;
Mair and McEntee, 1983). These studies support the prediction
that patients with AD who have LC degeneration display deficits
in selective attention.
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Animal Behavior and the Locus Coeruleus
A number of procedures have been used to study the role
of LC noradrenergic neurons in behavior. Because the LC is
the major source of cortical NE, pharmacological techniques
are particularly relevant. This approach uses drugs that fall
into one of several categories: synthesis blockers (e.g. diethyl
dithiocarbamate [DEDTC] and bis[4-methyl-l-hompiperazinylthiocar-
bonyl] isulphide [FLA-63]), neurotoxins (e.g. 6-hydroxydopamine
[6-OHDA]), receptor blockers (e.g. propranolol), reuptake blockers
(e.g. desipramine), MAO inhibitors (e.g. iproniazid), and receptor
agonists (e.g. clonidine).
Synthesis blockers have been used in a large number of
studies. The results indicate that this manipulation may impair,
enhance, or have no effect on retention depending upon the training
regime and retention intervals employed (Quartermain, 1983).
The first study that demonstrated that depletion of NE can impair
memory was a study by Krantz and Seiden (1968). These investigators
found that DEDTC administered 24 hours after learning disrupted
retention when rats were tested 6 hours following drug treatment
but not at longer times. Spontaneous recovery following amnesia
induced by the use of synthesis blockers has been reported in
several other studies. For example, Botwinick, Quartermain,
Freedman, and Hallock (1977) found that amnesia for a multiple-trial
discrimination task induced by FLA-63 was present 24 hours after
training, but full recovery was observed at 48 hours. A similar
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recovery from amnesia was reported after the administration
of DEDTC (Freedman, Backman, and Quartermain, 1979). Quinton
and Bloom (1977) demonstrated that administration of d-amphetamine
30 minutes before testing induces recovery of memory in DEDTC-treated
mice who had failed to show spontaneous recovery. A study by
Izquierdo, Beamish, and Anisman (1979) investigated the amnestic
effects of FLA-63 on four different avoidance tasks in mice.
Results showed that pre- but not post-training resulted in amnesia
in three of the four tasks. The drug did not disrupt retention
of a task requiring immobility to avoid shock. This experiment
confirmed several findings reported by Botwinick et al., (1977).
Taken together these results suggest that NE is involved in
spontaneous recovery of memory and that improved performance
is not due to transient FLA-63 or DEDTC toxicity.
Rainbow, Adler, and Flexner (1976) compared the amnestic
effects of 6-OHDA treatment to those induced by the protein
synthesis inhibitor cycloheximide. Retention was tested 6 hours
and 24 hours posttraining. The results of this study indicated
that whereas cycloheximide-induced amnesia disrupted retention
at both retention intervals, 6-OHDA-treated mice were amnestic
only at the 24-hour test. Flexner and Rainbow (1978) reported
that mice with 6-OHDA lesions of the dorsal bundle displayed
amnesia for a multiple trial discrimination task 24 hours after
learning but not 72 hours after learning, also implicating NE
in the phenomenon of spontaneous recovery. It should be noted
that the dorsal bundle is the major efferent pathway of the
36
LC.
Crow and Wendlandt (1976) examined the effects of depletion
of hippocampal and forebrain NE by injecting 6-OHDA bilaterally
into the LC. Rats were subsequently trained on a passive avoidance
task and retention tested immediately and 72 hours posttraining.
Acquisition and immediate retention were normal, but significant
retention deficits were observed at the 72-hour retention interval.
Increased resistance to extinction appears to be the most
obvious sequela of depletion of NE (Masoh and Iversen, 1979).
Lorden, Rickert, Dawson, and Pelleymounter (1976) reported that
rats with 6-OHDA lesions of the dorsal bundle failed to suppress
previously learned behavior after reinforcement was discontinued.
These results are consistent with the hypothesis that NE plays
a role in selective attention. It has been suggested that NE
could promote learning and facilitate retreival by suppressing
irrelevant background information while amplifying inputs from
significant environmental stimuli (Segal and Bloom, 1976).
Animals with reductions in brain NE would thus be expected to
display increased resistance to extinction as a result of impaired
attention to the new task demands. Mason and Iversen (1979)
reported that rats with dorsal bundle lesions were more distractable
than normal animals, providing further support of this hypothesis.
Similar observations have been made concerning rats with hippocampal
lesions (Mason and Iversen, 1979), raising the possibility that
the hippocampus mediates some of the behavioral effects of NE.
This conclusion is supported by the numerous behavioral deficits
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common to rats with dorsal bundle lesions and hippocampal lesions.
Both result in reduced spatial alternation, improved reversal
learning in spatial tasks, impaired light/dark discrimination
and reversal learning, increased resistance to extinction, failure
to display blocking in the non-reversal shift paradigm, reduced
latent inhibition, decreased habituation, and neophobias'
to novel environments (Mason and Iversen, 1975; Mason and Iversen,
1979; Mason and Iversen, 1978 a,b,c; Lorden et al., 1976;
Mason and Fibiger, 1978; Mason and Fibiger, 1979).
A number of investigators have noted that rats with 6-OHDA
lesions of the dorsal bundle displayed deficits in selective
attention (Mason and Iversen, 1978; Lorden et al., 1976).
These same animals had significantly decreased levels of forebrain
NE. Segal and Bloom (1976), on the basis of electrophysiological
evidence, proposed a role for NE in selective attention. Mason
and Iversen (1978) suggested that the LC is involved in "filtering
out irrelevant stimuli," based on behavioral data. Other investi-
gators have concluded that rats with dorsal bundle lesions are
unable to ignore redundant stimulus information (Lorden et al.,
1976), consistent with the hypothesized role of NE in selective
attention. These findings lead to the prediction that in the
human subject, LC degeneration secondary to AD will result in
deficits similar to those observed in experimental animals.
Recently, Arnsten and Goldman-Rakic (1983) demonstrated
that the alpha-2 noradrenergic agonist clonidine can ameliorate
the cognitive deficts exhibited by aged nonhuman primates on
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a delayed-response task. These investigators noted that there
is an age-related decline in brain levels of NE in man and animals.
The results of this study demonstrate that the noradrenergic
system contributes to cognitive function. Furthermore, the
demands of the delayed-response task require the subject to
ignore one or more identical food wells, and thus the task requires
the means to filter out irrelevant stimuli.
Other aspects of attention will be reviewed in the following
section, particulary as they relate to the human. It will be
shown that selective attention is the domain most likely to
be impaired in patients with LC pathology, consistent with the
results of studies using experimental animals.
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The Role of NE in Human Cognition
The discovery of LC neuropathology in patients with
AD, as well as the failure of ACh precursor treatment, argue
that the role of NE in human cognition must be investigated.
Several lines of evidence from the animal literature suggest
that the noradrenergic system is involved in memory (Quartermain,
1983) and selective attention (Segal and Bloom, 1976; Lorden
et al., 1976; Mason and Fibiger, 1978 a,b), as reviewed
in the preceding section. The present discussion is confined
to the clinical literature, including the cognitive impairments
associated with aging and Korsakoff's syndrome (KS).
Attention is not a unitary factor and has been subdivided
into three realms: vigilance, arousal, and selective attention
(Posner, Nissen, and Ogden, 1978). Davies and Griew (1965)
reviewed the literature on the effects of aging on vigilance.
These investigators concluded that there is not a consistent
effect due to age in studies of vigilance. Davies and Griew
(1965) also concluded that vigilance and arousal interact.
Rosvold, Mirsky, Sarason, Bransome, and Beck (1956) reported
that patients with senile dementia were impaired on a vigilance
task which they called the Continuous Performance Test.
It should be noted that the deficits observed in this group
of patients could be attributed to impairments in selective-
attention, rather than vigilance, due to the nature of the
task, which required subjects to respond to a target sequence
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of letters and to ignore irrelevant sequences of letters.
This report illustrates the difficulty involved in separating
aspects of attention. It has been argued that the effect
of arousal on test performance is due to motivational factors,
which are subject to individual differences and are difficult
to assess reliably (Davies and Griew, 1965). Selective
attention has been defined as the ability to ignore redundant
or irrelevant stimuli (Segal and Bloom, 1976; Lorden et
al., 1976; Mason and Iversen, 1978a), and it is this realm
of attention which is most likely to be impaired in patients
with LC degeneration, as noted in the previous section.
Mair and McEntee (1983) believe that KS has two major
advantages as a human model of central NE impairment. First,
KS is associated with a consistent pattern of pathology
that is restricted to medial regions of the brainstem and
diencephalon (Victor and Adams, 1953). The LC lies on the
floor of the fourth ventricle, an area of the brainstem
affected by KS (Victor and Adams, 1953). Second, KS is
associated with a homogenous and circumscribed pattern
of cognitive impairment' (Mair and McEntee, 1983, p. 9),
consistent with the impairments in selective attention displayed
by animals with 6-OHDA lesions of the dorsal bundle (Lorden
et al., 1976; Mason and Fibiger, 1978). McEntee, Mair,
and Langlais (1982) reported that patients with KS had signi-
ficantly reduced levels of MHPG in lumbar CSF, further evidence
that KS is associated with central NE impairment.
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The reductions in CSF MHPG observed in patients with
KS had a small effect on overall intelligence (McEntee,
Mair, and Langlais, 1982), as measured by the Wechsler Adult
Intelligence Scale (WAIS). Patients with KS were impaired,
however, on two subtests of the WAIS, Digit-Symbol substitution
and Object Assembly. In addition, patients were significantly
impaired on Wechsler Memory Scale (WMS) subtests that measure
recall of a brief story, visual reproduction, and associative
learning.
When patients with KS were given the noradrenergic
alpha-2 agonist, clonidine, a significant improvement was
noted in the WMS subtests that measure visual reproduction
and story recall (Mair, McEntee, and Zatorro, 1982). For
21 patients with KS, a positive correlation was observed
between levels of MHPG in CSF and performance of the memory
passages, associative learning, and visual reproduction
(Mair, McEntee, and Zatorro, 1982). There is no explanation,
however, as to why clonidine, a drug that decreases NE release
in normal subjects due to agonistic effects exerted on alpha-2,
presynaptic autoreceptors, should improve memory performance
in patients with KS, who have reduced levels of NE. It
is possible that changes in receptor sensitivity and number
may mediate the therapeutic effects of clonidine in patients
with KS.
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Talland (1965) studied the cognitive impairments observed
in patients with KS. He found that although KS patients
were capable of resisting distraction in a simple task,
they displayed diminished orientation responses and were
strikingly impaired in their ability to shift the focus
of attention in a digit-span task. Talland also noted that
the performance of KS patients on a motor task decayed more
quickly than did that of normal subjects when required to
divide attention. Talland remarked that the capacity to
shift the focus of attention involves the ability to attend
to a relevant set of stimulus cues and subsequently to refocus
attention. Talland's (1965) study suggests that patients
with KS display deficits in selective attention that are
similar to those displayed by animals with 6-OHDA lesions
of the dorsal bundle (Segal and Bloom, 1976; Lorden et
al., 1976; Mason and Fibiger, 1978 a,b,c).
Mair and McEntee (1983) measured the orientation responses
of KS patients to an auditory stimulus and found that they
had smaller initial galvanic skin responses and habituated
less rapidly than did brain-damaged control subjects, consistent
with Talland's (1965) findings. When the patients with
KS were given clonidine, they showed improved memory performance
and orientation, with galvanic skin responses approaching
normal amplitude and normal rate of habituation. These
results are consistent with the hypothesis that attention
is dependent upon the level of central NE activity. The
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implication of deficits in selective attention in KS thus
provides a mechanism that may account for other deficits
associated with this syndrome (Mair and McEntee, 1983).
Given the findings in patients with KS, it is likely
that AD patients with reduced levels of MHPG secondary to
LC degeneration will display deficits in selective attention.
A role for NE neurons in selective attention is consistent
with observations drawn from studies of experimental animals
(Segal and Bloom, 1976; Lorden et al., 1976; Mason and
Fibiger, 1978 a,b,c).
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Previous Studies of Forgetting in Amnesic Patients
In humans, global amnesia can result from damage to
a variety of brain structures and can be consequent to a
number of neurological conditions. The etiologies considered
in the present discussion involve either diencephalic or
medial temporal-lobe structures bilaterally. Specifically,
lesions in the dorsomedial nucleus of the thalamus and the
mamillary bodies are the neuropathological hallmarks of
the amnesia seen in Korsakoff's syndrome (Victor and Adams,
1953; Victor, Adams, and Collins, 1971; Mair, Warrington,
and Weiskrantz, 1979); lesions of medial temporal-lobe structures
are also implicated in global memory disorders, as epitomized
by the famous neurological patient H.M. This patient underwent
a bilateral medial temporal-lobe resection in 1953 and has
had a profound anterograde amnesia since that time (Scoville
and Milner, 1957; Milner, Corkin, and Teuber, 1968; Corkin,
1984).
L'Hermitte and Signoret (1972) hypothesized that amnesias
can take different forms related to the site of neuropathology.
Huppert and Piercy (1979) reported that H.M. displayed rapid
forgetting in relation to control subjects, whereas patients
with diencephalic pathology due to Korsakoff's syndrome
did not. Huppert and Piercy (1979) argued that there was
a functional basis for distinguishing amnesias associated
with lesions in medial temporal-lobe structures from amnesias
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associated with lesions in the medial thalamus and mamillary
bodies. The evidence for this distinction came from studies
with a picture-recognition technique in which amnesic patients
were provided additional study time in order to make their
initial yes-no recognition performance comparable to that
of control subjects (Huppert and Piercy, 1978). Forgetting
was then assessed 24 hours and 1 week later.
Huppert and Piercy's (1979) study is flawed, however.
H.M.'s initial performance was below that of control subjects,
despite Huppert and Piercy's attempt to equate H.M.'s initial
performance to that of control subjects. Huppert and Piercy's
conclusion that medial temporal-lobe pathology is associated
with rapid forgetting is therefore open to question.
Also problematic is the interpretation of Squire's
(1981) experiments with the same paradigm, which he cited
as supporting Huppert and Piercy's view. Squire found that
patients tested 2 hours after electroconvulsive therapy
(ECT) displayed rapid forgetting for sentences relative
to their performance on another form of the sentence test
administered 4 months later, and relative to the performance
of a patient (N.A.) with well-localized damage to the dorsomedial
nucleus of the left thalamus. This latter patient showed
a rate of forgetting similar to that of control subjects.
These findings provide only weak support for Huppert and
Piercy's view that medial temporal-lobe pathology is associated
with rapid forgetting because the brain areas implicated
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in the memory disorder seen after ECT have not been identified.
Squire's presumption that bilateral involvement of the medial
temporal lobes causes the memory disorder after ECT was
based upon indirect evidence (Inglis, 1970) and on Huppert
and Piercy's questionable results with H.M.
A recent study (Freed, Corkin, and Cohen, manuscript
submitted) calls into question Huppert and Piercy's (1979)
conclusion that medial temporal-lobe pathology is associated
with rapid forgetting. This study employed a picture-recognition
task, incorporating a two-alternative forced-choice format
(also called delayed-match-to-sample or DMS) in addition
to the yes-no format that Huppert and Piercy used. When
the mean of several test administrations was examined, H.M. dis-
played a normal rate of forgetting over a 1-week delay interval
using both yes-no and DMS procedures. Further, we have
subsequently shown that H.M.'s DMS and delayed-non-match-to-
sample (DNMS) recognition 6 months after learning was similar
to that of control subjects (Freed and Corkin, 1985), although
H.M.'s yes-no recognition at this delay interval was at
a chance level. The DMS and DNMS data are at variance with
Huppert and Piercy's claim that bilateral lesions in medial
temporal-lobe structures cause accelerated forgetting.
Taken together, these results argue that the amnesia due
to a radical resection of the medial temporal-lobes cannot
be explained by abnormally rapid forgetting, provided that
initial learning has been equated.
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H.M.'s memory disorder resulted from surgical excision
of medial temporal-lobe structures (Scoville and Milner,
1957; Milner, Corkin, and Teuber, 1968; Corkin, 1984).
The memory disorder associated with AD is believed to be
due at least in part to pathology in the same areas (Whitehouse
et al., 1981; Hyman, Van Hoesen, Damasio, and Barnes, 1984).
Therefore, the role of medial temporal-lobe structures in
forgetting should be investigated further in patients with
AD.
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EXPERIMENT 1
Rate of Forgetting in Alzheimer's Disease
It is conceivable that the unrecognized existence of
subgroups of patients related to neurotransmitter abnormality
has precluded the identification of drugs useful in the
treatment of AD (Corkin, 1981). The characterization of
neurotransmitter-related subgroups of patients with AD would
therefore allow tailoring of treatments to specific patient
groups. The premorbid identification of subgroups of patients
with AD would also have profound implications for studies
concerned with etiology because different patterns of neuro-
pathology are likely to be related to different causes.
Attempts to distinguish behavioral subgroups have focused
on initial symptom. It has been noted that the largest
subgroup includes those patients with a memory disorder
as the initial symptom (Corkin, 1981). L'Hermitte and Signoret
(1972) hypothesized that amnesias can take different forms
related to the site of neuropathology. Huppert and Piercy
(1979) used a picture-recognition paradigm to study rate
of forgetting in patient H.M. and in patients with KS, as
discussed in the preceding section. The following experiment
explored the possible existence of subgroups of patients
with AD, focusing on memory performance, while testing Huppert
and Piercy's (1979) hypothesis that medial temporal-lobe
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pathology is associated with rapid forgetting.
Method
Subjects
The subjects were 10 men and 10 women with AD and 8
healthy men and 12 healthy women, matched to the patients
on the basis of age and educational background (Table 1).
The patients had a clinical diagnosis of AD made in accordance
with recent NINCDS and NIA diagnostic guidelines (McKahn
et al., 1984; Khachaturian, 1985). The 20 patients had
a mean Blessed Dementia Scale Score (BDS) of 15.6 (range:
5 - 30). Patients with a BDS score below 10 were considered
mildly demented, those patients with a score of 10 to 19
moderately demented, and those patients with a score over
19 severely demented. Healthy elderly subjects scored from
0 - 3 on the BDS and were not demented according to DSM-III,
NINCDS, and NIA criteria. All patients with AD had evidence
of memory impairment on neuropsychological testing.
Test Materials
A picture-recognition procedure was chosen for this
investigation because the technique is ecologically valid,
is pleasurable for the subjects, and allows the matching
of initial recognition performance across patients who vary
in the severity of their memory disorder.
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Table 1
Characteristics of Control Subjects and Patients in Experiment 1
Group
Healthy Elderly
Subjects
Patients with
Alzheimer's Disease
Male Female
8
10
12
10
Mean Age
(years)
63.4
65.6
51
Mean Ed
(years)
13.1
13.5
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Four different forms of the picture-recognition test
were constructed from a total of 720 color slides of complex
photographs reproduced from foreign language magazines.
The material for each form of the test was organized into
2 sets of 90 slides: 1 set was designated to serve as targets
and the other set as distractors. Each set of 90 slides
was matched on the basis of content, containing an equal
number of slides from each of 6 categories related to the
subject of the slide: animals, buildings, interiors, people,
nature, and single objects. The target set and the distractor
set were then organized separately into three sets of 30
slides, which were used to construct the three retention
tests for each form of the picture-recognition test. Each
set of 30 contained an equal number of slides from each
of the six categories related to the subject of the slide.
In assembling the pairs of slides used in recognition testing,
one of the 30 target slides was randomly paired with one
of the 30 distractor slides and assigned a position in the
retention test. This procedure was repeated in constructing
the three retention tests for each form. In this manner,
the three retention tests were balanced with respect to
content. The presentation set was assembled using duplicate
slides of the full set of targets, which were randomly assigned
to 1 of the 90 positions in the learning phase.
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Procedure
Subjects were tested individually. In the learning
phase, control subjects viewed each target slide for 1 second.
The exposure time for patients with AD ranged from 4 to
16 seconds. The greater the severity of dementia, as measured
by the BDS, the longer the exposure time required to bring
the patient to the same level of initial learning as control
subjects. The interstimulus interval for all subjects was
approximately 750 msec. All targets were shown in the learning
phase, and again in 1 of 3 tests in the retention phase,
where each target was paired with a distractor. Recognition
performance was assessed using a DMS procedure, which has
been shown to be easier, as well as more reliable, for amnesic
subjects (Freed, Corkin, and Cohen, manuscript submitted).
In this procedure, the subject is shown a target and a distractor
and is asked "Which is the old picture?" All subjects were
tested 10 minutes, 24 hours, and 72 hours after the end
of the learning phase.
Results
Data on three versions of the test given to the 20
control subects were examined. One of the three versions
of the test was carefully scrutinized for differences in
the degree of difficulty between subtests. A Latin Square
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ANOVA with 3 subjects in each cell was performed on these
data. This analysis indicated that there were no systematic
differences between subtests in this version (F(2,18) =
3.02, > .05). For the other three versions, a comparison
of the mean score on each subtest in each of three orders
failed to reveal any systematic differences between subtests.
It is thus reasonable to conclude that there were no significant
differences between subtests in terms of degree of difficulty.
Figure 1 presents the mean percent correct for 20 patients
with AD and 20 control subjects at the three delay intervals.
A repeated measures ANOVA performed on the data indicated
that the two groups did not differ with respect to overall
forgetting (F(1,38) = 2.55, > .05). A main effect for
time was noted whereby scores for both groups were lower
at the longer delay intervals (F(2,76) = 58.96, < .01).
The group x time interaction was significant (F(2,76) =
14.9, < .01), reflecting a large difference between the
performance of the two groups 24 hours after learning, when
the patients performed worse than the control subjects (t(19)
= 2.8, < .01). At 72 hours, however, there was no difference.
This result is due to the fact that 10 of the 20 patients
with AD displayed a rebound in recognition performance 72
hours after learning, whereas 10 did not (Figure 2). None
of the control subjects displayed a rebound in recognition
performance (Figure 2).
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Figure 1. DMS recognition of 20 patients with AD and 20
control subjects, as assessed in Experiment 1. The verti-
cal bars through the data points represent a range of plus
or minus one standard error of the mean.
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Figure 2. DMS recognition of two subgroups of patients
with AD, as assessed in Experiment 1. The data for the
control subjects are included for comparison. The verti-
cal bars through the data points represent a range of plus
or minus one standard error of the mean.
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II
The present study identified a subgroup of patients
with AD who displayed impaired recognition 24 hours after
learning, followed by a rebound in recognition performance
72 hours after learning. Posthoc analyses of the data revealed
a significant correlation between the magnitude of the rebound
in recognition and performance on a selective attention
task (Pearson's r = .38, < .10). The attentional focusing
test was modeled after a paradigm developed by Posner, Nissen,
and Ogden (1978). In addition, post hoc analyses revealed
a relationship between anomalous performance on the picture-
recognition.task and anomalous performance on this test
of selective attention. A Chi-Square analysis revealed
a significant correlation (Chi-Square = 11.55, < .005)
between anomalous performance on these two tasks (Tables
2 and 3).
All 10 patients who displayed a rebound in DMS recognition
performance did so at the 72-hour retention interval, and
their performance profile resembles the letter V when graphically
presented (Figure 2). Of the 10 patients who displayed
a rebound in DMS recognition performance, 6 were females
and 4 were males. The other possible pattern of rebound
performance, that which resembles an inverted V when graphed,
was not observed in this experiment.
BDS scores for the two groups of patients (those that
displayed a rebound in recognition performance and those
that did not) were also examined. There were no significant
57
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Table 2
Chi Square Data for Patients (Experiment 1)
Attentional
Expectancy Effect
Focusing Test
No Expectancy Effect
AD Subgroup 1
(Nonrebound)
AD Subgroup 2
(Rebound)
8 0 8
3 7 10
11 7 18
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Table 3
Chi Square Data for Control Subjects (Experiment 1)
Attentional
Expectancy Effect
Focusing Test
No Expectancy Effect
No Rebound
in DMS
performance
Rebound
in DMS
performance
10 0 10
0 0 0
10 0 10
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differences between the two groups with regard to severity
of dementia (t (19) = 0.07, > .50). Furthermore, the
groups did not differ with respect to age, age at onset,
or duration of disease (Table 4).
Discussion
Over a 72-hour delay interval, patients with AD displayed
normal forgetting of pictorial stimuli. These results are
in accord with the findings of Kopelman (1985), who reported
that patients with AD displayed normal rates of forgetting
after a one-week delay. The findings of an earlier study
of forgetting in H.M., as well as the findings of the current
study, indicate that abnormally fast forgetting over extended
delay intervals is not a consequence of medial temporal-lobe
pathology. Taken together, these results suggest that there
are no human disorders characterized by rapid forgetting
of visual information when assesed with DMS recognition
procedures.
Squire (1981) tested patients on a similar task immediately
after ECT and found that these patients displayed rapid
forgetting relative to control subjects 32 hours after learning.
Squire's conclusion that these results support Huppert and
Piercy's hypothesis may have been premature, however. The
deficit observed by Squire 32 hours after learning may be
comparable to the decrement in performance observed at the
60
Table 4
Characteristics of Patients in Experiment 1
Mean Age Mean Ed
Male Female (years) (years)
AD Subgroup 1
(Nonrebound)
AD Subgroup 2
(Rebound)
6 4
4 6
63.8
66.6
13.1
14.1
Duration Onset
BDS (years) (age)
17.2 2.7
16.8 4.3
61.1
62.3
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24-hour retention interval in the present study. Further
experiments with ECT patients, using 72-hour and 1-week
retention intervals, are needed to resolve this question.
In this experiment, there was a significant association
between a rebound in DMS recognition and anomalous performance
on a test of attentional focusing. These data suggest the
existence of a subgroup of patients with AD who have deficits
in the realms of memory and selective attention, as predicted.
The phenomenon observed in Experiment 1, a rebound in DMS
recognition performance, was unexpected. Little information
exists regarding this phenomenon in humans, other than references
to the 'reminiscence effect" (Stevens, 1951), a term used
to describe an improvement in recognition performance observed
in normal subjects (particularly slow learners") over extended
delays. Accounts of similar phenomena are found in the
experimental animal literature; they provide insight into
possible anatomic and biochemical substrates. Most of these
accounts focus on the LC and changes in NE neurotransmission.
Given the existence of LC pathology in AD, the previous
work in animals concerning the behavioral role of the LC,
and the results of this experiment, it was hypothesized
that neuropsychological tests could identify a subgroup
of patients with deficits in the domain of selective attention,
secondary to LC pathology.
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EXPERIMENT 2
Selective Attention in Alzheimer's Disease
Next, a predictive study was undertaken to study the
relationship between anomalous performance on the picture-
recognition task and the selective attention task. The
following predictions were made: (1) as a whole, the patients
will display a normal rate of forgetting, (2) there will
be two patterns of DMS performance displayed by distinct
subgroups of patients, and (3) a rebound in DMS recognition
will be associated with abnormal performance on the test
of attentional focusing. It was further hypothesized that
neuropsychological tests can identify a subgroup of patients
with AD who have marked deficits in the domain of selective
attention, secondary to LC pathology.
The picture-recognition task was modified to include
both DNMS and DMS forced-choice recognition procedures.
This modification permitted the study of the interaction
of recognition memory and selective attention in patients
with AD by examining the relationship between DMS and DNMS
recognition performance.
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Method
Subjects
Subjects were 7 men and 13 women with AD, and 4 healthy
men and 10 healthy women matched to the patients for age
and educational background (Table 5). The 20 patients were
not participants in Experiment 1; they did have a clinical
diagnosis of AD, established by the same criteria as in
Experiment 1, and they were referred from the same source.
The 20 patients in Experiment 2 had a mean BDS score of
15 (range: 8 - 27). Thus, the patients in Experiment 2
were, as a group, similar to the previous group of patients
(Experiment 1) in terms of severity of dementia. Our control
subjects were not demented according to DSM-III, NINCDS,
and NIA criteria.
Test Materials
Four unique versions of the picture-recognition task
were constructed in the same manner as described in Experiment
1. In Experiment 2, each version consisted of 240 slides,
instead of 180, as in Experiment 1. This manipulation allowed
for the use of two different recognition procedures in assessing
recognition memory. A comparison of the performance of
4 control subjects on the 90 and 120 slide versions indicated
that the length of the test had no significant effect on
rate of forgetting.
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Table 5
Characteristics of Control Subjects and Patients in Experiment 2
Group
Healthy Elderly
Subjects
Male Female
4 10
Mean Age
(years)
60.2
Patients with
Alzheimer's Disease
Mean Ed
(years)
.13.2
7 13 63.9 13.8
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Procedure
Recognition testing procedures were the same as in
Experiment 1, except for the addition of the DNMS recognition
procedure. In DMS testing, the subject was asked Which
picture is old?" In DNMS testing, the subject was asked
'Which picture is new?"
Due to the significant posthoc correlation in Experiment
1 between anomalous picture-recognition performance and
anomalous performance on a test of attentional focusing,
the test of attentional focusing was incorporated into Experiment
2. Each of 90 test trials began with the presentation of
the message Get ready" on a video screen controlled by
an Apple II Plus microcomputer. After 5 seconds, the message
was replaced by a visual warning signal at the center of
the screen. The warning cue was accompanied by an auditory
signal. On one-third of the trials, the cue was an arrow
pointing right; on one-third, it was an arrow pointing left;
and on one-third, it was a doubleheaded arrow pointing both
left and right (neutral trials). Either 2 or 3 seconds
after the warning cue, an X appeared 3.7 degrees to the
right or the left of the arrow. The subject's task was
to press a single response key as fast as possible after
the appearance of the target. Subjects were instructed
that when the warning cue was a single arrow, the X would
probably appear in the direction of the arrow, and when
the warning signal was a double-headed arrow, the two locations
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were equally likely. The single arrow cues were valid 80%
of the time (expected trials); on the remaining 20% of the
single arrow trials, the X appeared on the side opposite
the direction indicated by the arrow (unexpected trials).
Normal subjects benefit from the appearance of valid
single arrow cues, as shown in mean reaction times for the
different types of trials. The performance of normal subjects
was typified by the occurrence of a positive value for the
mean difference between unexpected and expected trials (in
other words, the mean of 2U-2E + 3U-3E). Anomalous performance
was typified by the occurrence of a negative value for the
mean difference between unexpected and expected trials.
Results
Figure 3 presents picture-recognition performance as
assessed using the DMS procedure in 20 patients with AD
and 14 control subjects. A repeated measures ANOVA indicated
that the two groups did not differ with respect to overall
forgetting (F(1,32) = 0.04, > .05). A main effect for
time was noted in that scores for both groups were lower
at the longer delay intervals (F(2,64) = 25.03, p < .001).
There was a significant group x time interaction (F(2,64)
= 3.34, < .05) due to the fact that 10 of the 20 patients
with AD displayed a rebound in DMS recognition performance
(Figure 4). This finding replicated the results of Experiment
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Figure 3. DMS recognition of 20 patients with AD and 14
control subjects, as assessed in Experiment 2. The verti-
cal bars through the data points represent a range of plus
or minus one standard error of the mean.
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Figure 4. DMS recognition of two subgroups of patients with
AD, as assessed in Experiment 2. The data for the control
subjects are included for comparison. The vertical bars
through the data points represent a range of plus or minus
one standard error of the mean.
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1 (Figure 2).
Figure 5 presents the mean percent correct recognition
as assessed using the DNMS procedure in the same two groups.
A repeated measures ANOVA indicated that they did not differ
with respect to overall forgetting (F(1,32) = 0.55, >
.05) in the DNMS procedure. A main effect for time was
noted in the lower scores for both groups at the longer
delay intervals (F(2,64) = 24.97, < .001). A near significant
group x time interaction was noted (F(2,64) = 2.53, p <
.10). Overall, the patients with AD displayed normal forgetting
when tested with either DMS or DNMS recognition procedures.
The more revealing findings relate to the existence
of subgroups of patients with AD. The DMS results of Experiment
2 replicated and extended the observations made in Experiment
1 in that half of the patients displayed anomalous performance,
as assessed by DMS recognition procedures. In addition,
the significant association between anomalous recognition
performance and anomalous performance on a test of attentional
focusing noted in Experiment 1 was replicated in Experiment
2 (Tables 6 and 7). A Chi-Square analysis of the data from
Experiment 2 revealed a significant correlation (Chi-square
= 13.3, E < .005) between anomalous performance on these
two tasks. The proposed classification scheme for patients
is thus supported by the DMS and attentional focusing data.
This categorization is further legitimized by the DNMS
data. For the patients who displayed a rebound in DMS recog-
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Figure 5. DNMS recognition of 20 patients with AD and 14
control subjects, as assessed in Experiment 2. The vertical
bars through the data points represent a range of plus or
minus one standard error of the mean.
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Table 6
Chi Square Data for Patients (ExPeriment 2)
Attentional Focusing Test
Expectancy Effect No Expectancy Effect
AD Subgroup 1
(Nonrebound)
AD Subgroup 2
(Rebound)
6 2 8
0 10 10
6 12 18
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Table 7
Chi Suare Data for Control Subjects (Experiment 2)
Attentional Focusing Test
Expectancy Effect No Expectancy Effect
No Rebound
in DMS
performance
Rebound
in DMS
performance
8 0 8
0 0 0
8 0 8
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nition, there was a strong negative correlation between
the magnitude of the rebound in DMS recognition and the
magnitude of the rebound in DNMS recognition (Pearson's
r -. 34, > .10). For the patients who did not display
a rebound in DMS recognition, there was a weak positive
correlation between the magnitude of the rebound in DMS
recognition and the magnitude of the rebound in DNMS recognition
(Pearson's r = -. 06, > .50). Thus, for the patients who
displayed a rebound in DMS recognition, there is a strong
negative correlation between the magnitude of that rebound
and the magnitude of a decrement in DNMS recognition.
BDS scores were examined for the two groups of patients.
There was no significant difference in terms of severity
of dementia for the two groups (t(19) = .24, a > .50) (Table
8). In addition, 6 of the 10 patients who displayed a rebound
in DMS recognition also displayed a rebound in DNMS recognition,
where a rebound in recognition is defined as any increase
in performance over time.
An ANOVA performed on the data from patients with AD
indicated that the order in which the DMS and DNMS procedures
were administered had no significant effect upon test performance
(F(1,18) = 0.54, > .20). In this analysis, the effect
due to time was significant (F(2,36) = 7.47, < .001).
The interaction between order of administration and time
approached significance (F(2,36) = 2.69, < .10), due to
the existence of a subgroup of 10 patients who displayed
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Table 8
Characteristics of Patients in Experiment 2
Mean Age
Male Female (years)
AD Subgroup 1
(Nonrebound)
AD Subgroup 2
(Rebound)
4
3
6
7
63.0
66.2
Mean Ed Duration Onset
(years) BDS (years) (age)
13.8
13.4
14.7 2.8
12.9 2.8
58.0
63.4
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a rebound in DMS recognition (Figure 4).
Discussion
The results of Experiments 1 and 2 indicated that patients
with AD displayed normal forgetting of pictorial stimuli
over a 72-hour delay interval provided that they are given
additional study time in order to equate their initial recog-
nition performance to that of control subjects. One criticism
of these experiments concerns the use of additional study
time for the patients relative to control subjects. The
learning experience of the two groups differs and conclusions
regarding overall forgetting are therefore tenuous, according
to this argument. It should be noted, however, that these
investigations were concerned with forgetting in patients
with AD, not with problems in acquisition. There are no
ideal means to equate the initial performance of two groups
of subjects that differ in terms of speed of acquisition.
For example, if both patients and control subjects were
given 10 seconds study time, the recognition of the control
subjects 72 hours after learning would be near ceiling perfor-
mance, preventing comparisons of forgetting in the two groups.
If both groups were given 1 second of study time, the recognition
of the patients with AD 72 hours after learning would be
near chance performance, again preventing comparisons of
forgetting. In addition, if the patients with AD were given
1 second study time it is likely that the existence of the
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subgroup of patients that displayed a rebound in DMS recognition
would have gone undetected.
The major finding of Experiment 2 was the identification
of a subgroup of patients with AD using behavioral testing.
Prehoc analysis of test data (based upon the findings of
Experiment 1) revealed a relationship between anomalous
performance on the picture-recognition task and anomalous
performance on an attentional focusing paradigm. The results
of Experiment 2 support the existence of a behavioral subgroup
of patients with AD who have deficits in visual selective
attention. For the patients who displayed a rebound in
DMS recognition, there was a strong negative correlation
between the magnitude of the rebound in DMS performance
and the magnitude of the rebound in DNMS performance. These
data suggest that shifting response biases underlie the
rebound in DMS recognition.
The cognitive changes observed in the subgroup of patients
displaying anomalous performance are consistent with a body
of literature concerned with behavioral deficits in animals
due to lesions of the ascending noradrenergic system (Segal
and Bloom, 1976; Lorden, et al., 1980; Botwinick et al.,
1977; Mason and Iversen, 1978; Rainbow and Flexner, 1978).
Based upon the data, it is reasonable to hypothesize that
the changes in visual selective attention observed in a
subgroup of patients with AD are associated with LC pathology
in the human.
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EXPERIMENT 3
CSF Monoamine Metabolites and Selective Attention
Experiment 3 evaluated the hypothesis that deficits
in selective attention are associated with reductions in
brain NE. In order to investigate the hypothesis that
impairments in selective attention are behavioral evidence
of LC pathology, a physiological measure of LC function
was required. Four alternatives exist to test the hypothesis
in living patients: examine brain biopsy material, examine
CSF levels of the metabolite of NE, administer pharmacologic
agents that are known to affect NE, or use positron-emission
tomography (PET) to image NE receptors. PET imaging of
receptors is a recent development (Farde, Hall, Ehrin, and
Sedvall, 1986) and noradrenergic receptors have not yet
been studied. CSF studies were performed because this approach
was judged to be the safest and easiest procedure. The
results of clinical trials of clonidine will be reported
in Experiment 4.
Recent reports of neuropathology in AD have suggested
that female patients displayed more severe LC degeneration
than did male patients (Bondareff et al., 1982; Iversen
et al., 1983). Of the AD patients who displayed a rebound
in DMS recognition in Experiments 1 and 2, there were nearly
twice as many females as males (13 vs 7). The possibility
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that male and female patients with AD differ with regard
to levels of monoamine metabolites in CSF was therefore
examined.
Reports on sex differences in the brains of controls
subjects are sparse (Carlsson, Nyberg, and Winblad, 1984).
Bowers (1972) noted that brain levels of 5-HIAA and HVA
do not vary with gender. Adolfsson et al. (1979) found
no sex differences in DA and HVA levels from 16 human brain
regions. Spokes (1979) did not detect any sex differences
in DA or NE concentrations in corpus striatum, substantia
nigra, red nucleus, or motor cortex. More recently, Carlsson,
Nyberg, and Winbald (1984) reported significantly lower
amounts of 5-HIAA in thalamus and higher levels of serotonin
in medulla oblongota of female subjects relative to male
subjects, but no other differences in a wide variety of
brain structures.
With regard to CSF studies in normal subjects, Ballenger,
Post, and Goodwin (1984), in a large and carefully controlled
study, noted that the only variable for which there was
a significant difference in group means between male and
female control subjects was GABA levels in subjects under
the age of 40. These authors found no significant sex differ-
ences in CSF levels of 5-HIAA, HVA, and MHPG. Recently,
Mayeux, Stern, Cote, and Williams (1984) measured CSF metabolites
in a group of 15 nondepressed, hospitalized patients with
either neuromuscular disorders or stroke for use as control
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subjects in a study of Parkinson's disease. The mean age
of this group was 65.5 years, and there was no significant
difference between the age of male and female control subjects
in this study (t(12) = .91, p > .1). There was no significant
difference between male and female control subjects with
regard to CSF levels of MHPG (t(12) = 1.49, .10 > p > .05),
although there was a nonsignificant trend for male subjects
to have higher MHPG levels. Taken together with the results
of autopsy studies, these findings provide no reason to
hypothesize sex-differences in CSF levels of 5-HIAA, HVA,
or MHPG in healthy elderly subjects. Therefore, if significant
sex-differences are noted in the CSF of patients with AD,
it must be presumed that these differences are a manifestation
of the disease process. Such an observation may provide
clues about etiology.
Method
Subjects
Subjects were 13 women and 9 men with AD for whom both
neuropsychological and CSF data were available. These 22
patients were participants in Experiments 1 and 2 and were
similar to the remaining participants for whom CSF data
were unavailable (Table 9). The 22 patients had a clinical
diagnosis of AD and were referred from the same source as
patients in Experiments 1 and 2. In addition, CSF data
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Table 9
Characteristics of Patients in Experiment 3
Mean Age Mean Ed Duration Onset
Male Female (years) (years) BDS (years) (age)
Participants
in
Experiment 3
9 13 64.8 13.4 15.9 3.5
Remaining
Participants
in
Experiments
1 and 2
8 10 65.1 13.8 15.2 2.7
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61.2
59.2
from a larger group of 57 patients with AD (31 women and
26 men) were examined for sex-differences.
Test materials
Samples of CSF were routinely drawn from patients with
AD seen at MIT's Clinical Research Center. The patient
remained recumbent overnight and a sample was drawn from
the lumbar sac. All subjects agreed to this procedure beforehand
and signed a consent form in the presence of witnesses,
in accordance with the procedures outlined by MIT's Committee
on the Use of Humans as Experimental Subjects. For CSF
data to be included in the present study, the patient had
to be medication free and the assay had to be performed
within 30 days of neuropsychological testing. In most cases,
the lumbar puncture was performed during the week in which
the neuropsychological testing occurred.
Procedure
HVA and free MHPG were measured by an LC-304B high
pressure liquid chromatography (HPLC) system coupled with
electrochemical detection (Bioanalytical Systems). The
detector consisted of a dual glassy-carbon electrode oriented
in a parallel-adjacent arrangement (potentials +800/650
mV vs. Ag-AgCl reference electrode, sensitivity 2 or 5 na/V).
Separation was achieved on a 250 x 4.6 mm Biophase ODS 5
um column (Bioanalytical Systems) preceded by a guard column,
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using a 0.05 M sodium acetate buffer with pH 5.0 (Baker
Analyzed Reagents). Distilled-deionized water was used,
and the buffer was filtered (Millipore HA: 0.45 um) and
degassed before use. Stock solutions of HVA, 5-HIAA, and
free MHPG were prepared in 0.1 N perchloric acid. Standard
curves ranging from 0-10 ng of HVA, 5-HIAA, and MHPG were
injected intermittently between CSF samples. CSF samples
were deproteinized, centrifuged, and injected directly onto
the HPLC column. The current ratio, expressed as the peak
height at the low potential electrode divided by that at
the higher potential electrode, and the retention time were
used to identify compounds. Linear regression on data from
the higher potential electrode was used to calculate amounts
of HVA, 5-HIAA, and MHPG.
Results
Data from the larger group of 57 patients with AD were
grouped according to gender; t-tests were performed, comparing
male and female patients with respect to levels of catecholamine
metabolites including MHPG, 5-hydroxy, indoleacetic acid
(5-HIAA, major metabolite of serotonin), and HVA (homovanillic
acid, major metabolite of dopamine). It was noted that
male and female patients differed with regard to levels
of MHPG (t(26) = 2.05, = .02), with males having significantly
higher levels of MHPG (8.76 vs 7.12, respectively) (Figure
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6). Male and female patients did not differ with regard
to levels of 5-HIAA (t(27) = 1.32, E = .123) or HVA (t(27)
= 1.43, = .083). Accordingly, the MHPG data for Experiment
3 were grouped according to gender.
Table 10 presents the data for the 22 patients who
were participants in Experiment 3, with the data grouped
according to anomalous performance on the picture-recognition
test and gender. A Chi-Square analysis revealed a near
significant association (Chi-Square = 2.745, .10 > > .05)
between anomalous performance on the picture-recognition
test and reduced levels of MHPG (Table 11). Anomalous picture-
recognition performance was defined by the occurrence of
an increase in DMS recognition performance, regardless of
the retention interval. In Experiments 1 and 2, 16 of the
20 patients who displayed a rebound in DMS performance did
so at the 72-hour retention interval. For this and the
following Chi-Square analysis, MHPG levels were reduced
to a bivariate distribution. An individual patient's MHPG
level was defined as normal if the value was equal to or
greater than the mean MHPG value for AD patients of the
same sex, as justified by analyses that revealed a significant
difference between MHPG levels in male and female patients.
Similarly, MHPG levels were defined as reduced only if that
individual's values were below the mean MHPG value for patients
of the same sex.
A related Chi-Square anlaysis (Table 12) revealed a
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Figure 6. Mean free MHPG in CSF for the full group of
57 patients with AD, as well as the group of 22 patients
who participated in Experiment 3. The vertical bars
through the data points represent a range of plus or
minus one standard error of the mean.
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Table 10
Data Relating to CSF MHPG (Experiment 3)
Mean CSF MHPG Levels
Females
AD Subgroup 1
(Nonrebound)
AD Subgroup 2
(Rebound)
9.55
6.26
13
Males
10.5
8.45
9
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Group
10.025
7.355
22
Table 11
Chi Square Data Relating to CSF MHPG (Experiment 3)
CSF MHPG Levels
Above Mean
For Same Gender
Below Mean
For Same Gender
AD Subgroup 1
(Nonrebound)
AD Subgroup 2
(Rebound)
7 2 9
75
12
12
9 21
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Table 12
Chi Square Data Relating to CSF MHPG and Performance on the
Test of Attentional Focusing (Experiment 3)
CSF MHPG levels
Above Mean
For Same Gender
Below Mean
For Same Gender
F
o Expectancy
c Effect
u
s
i
n
g No Expectancy
Effect
A
t
t
e
n
t
i
o
n
a
1
8 2 10
3 6
811
9
19
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significant correlation between anomalous performance on
the test of attentional focusing and reduced levels of MHPG
(Chi-Square = 4.242, E < .05). Anomalous performance on
the test of attentional focusing was defined by the occurrence
of a negative value for the mean difference between unexpected
and expected trials (in other words, the mean of 2U-2E +
3U-3E). In addition, a significant correlation between
CSF MHPG levels and performance on a test of attentional
focusing was noted when the data were ranked (Spearman's
r_= .57, < .01).
Discussion
The major findings of Experiment 3 concerned the significant
correlation between anomalous performance on the attentional
focusing test and reduced levels of MHPG. A near significant
correlation between deviant performance on the picture-recog-
nition test and reduced levels of MHPG was also noted.
When the data from both Experiments 1 and 2 were combined,
a significant association between anomalous performance
on the attentional focusing test and the picture-recognition
test was noted (Tables 13 and 14). These experimental results
support the hypothesis that reductions in brain NE result
in impairments in selective attention. The impairments
in selective attention displayed by the identified subgroup
of patients were associated with reduced levels of MHPG
89
Table 13
Chi Suare Data for Patients Rearding the Association Between
Anomalous Performance on Two Tests (Experiments 1 and 2)
Attentional Focusing
Expectancy Effect No Expectancy Effect
AD Subgroup 1
(Nonrebound)
AD Subgroup 2
(Rebound)
14 2 16
3 17 20
17 19 36
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Table 14
Chi Square Data for Control Subjects Reqarding the Association
Between Anomalous Performance, on Two Tests (Experiments 1 and 2)-
Attentional Focusing
Expectancy Effect No Expectancy Effect
No Rebound
in DMS
performance
Rebound
in DMS
performance
18 0 18
0 0 0
18 0 18
91
in CSF. Reduced MHPG levels were defined as those below
that of the mean value of same sex patients.
A comparison of neurotransmitter markers for male and
female patients revealed a significant sex difference for
MHPG, but not 5-HIAA or HVA found in the CSF of patients
with AD. An analysis of CSF from 57 patients with AD revealed
that male patients had significantly higher levels of MHPG
than did female patients. Given that recent reports indicate
that LC degeneration is more common in female patients with
AD than male patients, the occurrence of a gender-related
difference in levels of MHPG is consistent with what is
known about the neuropathology of AD.
A study of CSF biogenic amine metabolites was undertaken
by Young and Ervin (1984). These authors concluded that
there are many similarities between vervet monkeys and humans
with regard to monoamine CSF metabolites. Young and Ervin
(1984) noted that mean levels of 5-HIAA, HVA, and MHPG were,
respectively, 33%, 29%, and 17% higher in female vervet
monkeys relative to males, and that the same is also true
of humans. Although to date, studies of CSF taken from
healthy elderly subjects have not revealed significant sex
differences in levels of brain monoamines, Young and Ervin's
(1984) results suggest that this possibility should be re-
examined.
It is conceivable that gender-related differences in
LC cell density, morphology, or biochemistry predispose
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females to the type of AD neuropathology characterized by
LC degeneration. If this notion is true, then studies of
gender-related differences in catecholamine-containing neurons
will be important in the search for clues to the etiology
of AD. While clinical neurology and neuropathological studies
of human brain material provide no support for this supposition
as of yet, investigations using experimental animals provide
some interesting data. It is known that the highest density
of opiate receptors in the rat brain is found in the LC
(Messing etal.,1980). Messingetal. (1980) reported regionally
specific changes in both numbers and apparent affinities
of opiate receptors during aging, along with significant
sex differences. In aged female rats, there were decreases
in receptor densities in the midbrain and thalamus. In
aged male rats, opiate binding sites in the frontal poles
had a higher affinity than in younger animals, but there
was no decrease in receptor density in the midbrain LC.
While indirect, these results suggest that sex differences
in the LC may occur during aging.
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EXPERIMENT 4
Clinical Trials Using Clonidine
The previous experiments demonstrated that the picture-
recognition test and the test of attentional focusing identify
a subgroup of patients with deficits in selective attention.
These deficits are associated with reduced CSF levels of
MHPG, the major metabolite of NE. Assuming that MHPG levels
in CSF accurately reflect the metabolism of NE within intact
LC neurons, these results suggest that neuropsychological
tests are able to identify a subgroup of patients with AD
who have LC degeneration.
The hypothesis that LC noradrenergic neurons play a
role in selective attention in the human was further tested
using psychopharmacological procedures. In Experiment 4,
7 patients with AD were administered the noradrenergic agonist,
clonidine, in ascending doses. Clonidine is an antihypertensive
medication that reduces blood pressure by stimulating presynaptic
alpha-2 autoreceptors in the vasomotor center of the brain.
Clonidine is a potent autoreceptor-stimulating drug but
at higher doses it may also stimulate postsynaptic adrenergic
receptors (Cooper, Bloom, and Roth, 1982).
A number of studies suggest that there can be an abundance
of postsynaptic adrenergic receptors (both alpha-1 and beta)
in brain regions deprived of NE (U'Prichard, Greenberg,
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Sheehan, and Snyder, 1977; Bylund and Snyder, 1976; Alexander,
Davis, and Lefkowitz, 1975), providing evidence of up-regula-
tion. Down-regulation of postsynaptic beta-adrenergic receptors
is also known to occur. For example, desipramine, a potent
inhibitor of NE uptake that has only a minimal effect on
dopamine uptake (Cooper, Bloom, and Roth, 1982), has been
shown to reduce the sensitivity and density of beta-adrenergic
receptors in the brain (Pandey and Davis, 1981). It is
clear that the responsiveness of the beta-adrenergic recep-
tor complex is inversely related to the degree of prior
adrenergic stimulation (Freilich and Weiss, 1983). These
results suggest that due to receptor up-regulation, low
doses of clonidine may interact with postsynaptic adrenergic
receptors in AD patients with reductions in brain NE secondary
to LC degeneration. Clonidine would be expected, therefore,
to exert a therapeutic effect on cognition.
It was hypothesized that the subgroup of patients presumed
to have LC degeneration would show improvements in selective
attention during clonidine administration while other patients
would not. This hypothesis was based upon the work of McEntee
and Mair (1980), which was discussed in a previous section.
In addition, it was hypothesized that the picture-recognition
and attentional focusing tests would be useful in measuring
aspects of selective attention that are NE dependent. Psycho-
pharmacology thus provided the means to test the theory
that behavior is a sensitive indicator of LC function, as
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well as to investigate a rational treatment strategy for
a subgroup of patients with AD.
Method
Subjects
The subjects were 7 women with AD (Table 15). The
patients had a clinical diagnosis of AD based upon strict
diagnostic criteria, which were in accordance with recent
NINCDS and NIA diagnostic guidelines (McKahn et al, 1984;
Khachaturian, 1985). The 7 patients, with one exception,
did not participate in any of the previous experiments.
The 7 patients had a mean BDS score of 17.1 (range 9.0 -
26.0). The 7 AD patients who participated in this experiment
thus had evidence of memory impairment on neuropsychological
testing and were, as a group, similar to the participants
of Experiments 1 and 2 in terms of severity of dementia
(Table 15). Patients with a BDS score below 10 were considered
mildly demented, those patients with a score of 10 to 19
moderately demented, and those patients with a score over
19 severely demented.
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Table 15
characteristics of Patients in Experiment 4
Patient Group
Experiment 1
Experiment 2
Experiment 4
Mean Age
Male Female (years)
10
7
0
63.4
13
7
63.9
61.4
97
Mean Ed
(years)
13.1
13.8
14.7
Mean
BDS
15.6
15.0
17.1
-- -'
Drugs
The patients were administered clonidine in ascending
doses from .025 mg to .2 mg (Table 16) until side effects
(dry mouth, drowsiness, lowered blood pressure, or agitation)
were apparent. Medication was discontinued at that time.
In Table 16, WO denotes washout.
Test Materials
Two additional versions of the picture-recognition
test were constructed in the same manner as described in
Experiment 2, for use in this experiment. In addition,
materials were assembled for the administration of a series
of neuropsychological tests including the the Continuous
Performance Test (Rosvold et al., 1956), Stroop Color Naming
Test (Stroop, 1935), Rabbitt Card-Sorting Test (Rabbitt,
1963), Category Fluency Test (Fuld, Katzman, Davies, and
Terry, 1982), and Boston Naming Test (Kaplan, Goodglass,
and Weintraub, 1978). The Rabbitt Card-Sorting Test and
a new variant of the test of attentional focusing using
peripheral cues were not given to two subjects who entered
the study before these tests were ready.
Recognition testing procedures for the picture-recognition
test were the same as in Experiment 2. The test of attentional
focusing was also administered in the same manner as in
Experiment 2.
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Table 16
Dosages and Drug Schedule for Patients in Experiment
Test conditions/dosages
8/17/11 5/85 Base Plac .10 .20 WO
6/2/31 6/85 Base Plac .05 .10 WO
1/26/28 7/85 Base Plac .05 .10 .15 .20 WO
8/16/26 9/85 Base Plac .025 .05 .10 .15 .20 WO
6/25/18 9/85 Base Plac .025 .05 WO
11/20/22 10/85 Base Plac .025 .05 .10 .15 .20 WO
1/12/28 11/85 Base Plac .025 .05 .05 .10 WO
99
DOB
4
DOT
WO
- 1-- -------- -- -- -- -- ----- - -
Results
Performance on the picture-recognition test and the
test of attentional focusing was used to classify the patients
in terms of anomalous performance on the these tests, as
discussed earlier. Table 17 presents the age and BDS scores
for the two groups of patients classified in this manner.
Data from 1 patient were excluded from further analysis
because this patient was unable to complete one of the two
tests at baseline.
Table 18 presents the behavioral data for the 2 groups
of patients under two conditions, baseline and best dose
of clonidine. The best dose was determined through analysis
of behavioral test scores rather than by a human rater,
allowing more objective evaluation of drug effects. Best
dose was defined as the dose of clonidine that resulted
in test performance that was superior to performance on
other doses of the drug. The best dose for an individual,
therefore, was defined by the highest number of personal
bestsw relative to performance on the other doses. Note
that the group of patients presumed to have LC degeneration
displayed improved performance on the picture-recognition
and attentional focusing tests during the administration
of the best dose of clonidine, while the performance of
the other group of patients deteriorated (Table 18). In
this table, N denotes No rebound observed' and R denotes
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Table 17
Characteristics of Two Groups of Patients in Experiment 4
Patient Group
Mean Age
(years)
Mean Ed Mean Duration
(years) BDS (years)
AD Subgroup 1
(Nonrebound)
AD Subgroup 2
(Rebound)
Onset
(Age)
61.0
61.6
15.3
15.0
15.5
15.7
2.0
4.5
56.0
59.0
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Table 18
Performance of 6 Patients in Experiment 4
Subgroup 1
Nonrebound Group
(N=3)
Subgroup 2
Rebound Group
(N=3)
Picture-recognition
Baseline
Clonidine
Attentional focusing
Baseline
Clonidine
Stroop Color Naming Test
Baseline
Clonidine
Category fluency
Baseline
Clonidine
Boston Naming
Baseline
Clonidine
N, N, N
N, R N
R, R R
R, N R
+83.7
+14.3
-101
+167
12.6
15.0
6.0
9.7
31.3
37.0
15.3
17.3
28.3
28.0
25.6
27.0
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Test
'Rebound observed" in DMS recognition. One of the patients
who displayed a rebound in DMS recognition at baseline did
not display a rebound in DMS recognition while taking clonidine.
Because the rebound phenomenon is reliable and replicable
in individual patients, this result suggests that pharmacologic
manipulation of the noradrenergic system may be a useful
treatment for the subgroup of AD patients with presumed
LC degeneration.
Table 19 presents data from the picture-recognition
test for the two groups of patients at baseline and best
dose of clonidine. Note that the patients who displayed
a rebound in DMS recognition at baseline benefited more
from the administration of clonidine than did the other
group of patients (Chi-Square = 2.71, < .10).
Discussion
The results of Experiment 4 support the hypothesis
that behavioral tests are a sensitive indicator of LC degene-
ration. In this experiment, the differential response to
clonidine of two groups of patients categorized on the basis
of behavioral testing provided further support of the hypothesis
that deficits in selective attention are associated with
reductions in brain NE. The subgroup of patients presumed
to have LC degeneration displayed improved performance on
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Table 19
Decline in Performance on the Picture-Recognition Test Between
the 10-Minute and 24-Hour Retention Intervals in Experiment 4
Baseline
10min - 24hrs
Best Dose
10min - 24hrs
AD Subgroup 1
(Nonrebound)
N=3
AD Subgroup 2
(Rebound)
N=3
16.7
26.7
5.0
3.3
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the picture-recognition test and test of attentional focusing
while taking clonidine. The performance of the other subgroup
of patients on these two test deteriorated during clonidine
administration.
In addition, the results of Experiment 4 suggested
that NE plays a role in word-finding difficulties in patients
with AD. Of the 6 female patients whose performance was
classified according to procedures described earlier, 2
had significant word-finding problems, as reported by family
members. Both of the patients with word-finding difficulty
were members of the subgroup of patients who displayed anomalous
performance on the picture-recognition and attentional focusing
tests. The language performance of these 2 patients improved
on clonidine, as revealed by observations made by testing
staff (Marie Wininger and David Freed, personal observations)
and spontaneous reports by family members. These results
suggest that word-finding difficulty in patients with AD
may be associated with reduced levels of brain NE. Unfor-
tunately, the standard neuropsychological tests used to
study language function were not sensitive to these changes
in performance (Table 18). It is possible that the repeated
use of the same test stimuli in multiple conditions (i.e. differ-
ent dosages) may have allowed patients with language difficulties
to learn the correct responses to test items on the Boston
Naming, Naming to Definition, and Word-list Learning tests.
The suggestion that NE plays a role in language function
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is consistent with two lines of evidence. Recent neuropatho-
logical studies suggest that female patients with early-onset
AD are more likely than male patients to display significant
LC degeneration (Bondareff et al., 1982; Iversen et al.,
1983; Bondareff, 1983). Clinical studies suggest that
early-onset AD is associated with an earlier and more severe
language disorder (Breitner and Folstein, 1984; Folstein
and Breitner, 1981; Mayeux, Stern, and Spanton, 1985;
Chui et al., 1985). These studies suggest that females
with early-onset AD may have a high incidence of LC degeneration,
which is associated with an earlier and more severe language
impairment. The results of the previous experiments support
the theory that LC degeneration is associated with impairments
in selective attention and picture-recognition. The results
of the present experiment suggest that word-finding difficulty
may also be a sensitive behavioral index of LC function.
With regard to this suggestion, it should be noted that
all 6 of the patients who were administered clonidine displayed
modest improvements in their scores on language tests (Appendices
3-8). This observation is consistent with reports from
the human literature of an age-related decline in brain
NE levels (Adolfsson, 1978) and with reports from the animal
literature suggesting that age-related declines in cognitive
performance can be alleviated by the administration of clonidine
(Arnsten and Goldman-Rakic, 1985)'.
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GENERAL DISCUSSION
It was hypothesized that neuropsychological tests can
distinguish a subgroup of patients with AD who have LC pathol-
ogy. Anomalous performance on the picture-recognition task
and the attentional focusing test were significantly correlated
in Experiments 1 and 2, suggesting that a deficit in visual
selective attention underlies anomalous performance in both
tasks. It was suggested that the impairments in selective
attention observed in a subgroup of patients with AD were
the result of a bias to novel locations or stimuli. This
type of bias would produce the pattern of results observed
in both the picture-recogntion and attentional focusing
tasks.
The hypothesis that reductions in brain NE secondary
to LC degeneration result in anomalous performance was tested
in Experiment 3. When the MHPG data were grouped according
to gender, as justified by experimental findings, a significant
correlation between anomalous performance and reduced levels
of MHPG was noted. In Experiments 1 and 2, it was noted
that there were nearly twice as many female patients who
displayed a rebound in DMS recognition performance as male
patients (Table 20), consistent with the finding that female
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Table 20
Characteristics of Two Groups of Patients in ExPeriments 1 and 2
Mean Age Mean Ed Duration Onset
Male Female (years) (years) BDS (years) (age)
AD Subgroup 1
(Nonrebound) 10 10 63.4 13.5 16.0 2.8
AD Subgroup 2
(Rebound) 7 13 66.4 13.8 14.9 3.6
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59.6
62.9
patients with AD had significantly lower levels of MHPG
than did male patients. These results are consistent with
neuropathological studies, which have noted that female
patients are more likely to display severe LC degeneration
than male patients (Bondareff et al., 1982; Iversen et
al., 1983).
A number of findings suggest sex differences in patients
with AD: (1) neuropathological reports indicate that female
patients with AD are more likely to possess severe LC degen-
eration (Bondareff et al., 1982; Iversen et al., 1983;
Arai et al., 1984); (2) nearly twice as many female patients
displayed a rebound in DMS recognition and anomalous performance
on a test of attentional focusing relative to male patients
with AD (Experiments 1 and 2); and, (3) female patients
with AD had significantly lower levels of MHPG in CSF than
did male patients (Experiment 3). Given the existence of
sex-differences in patients with AD, it becomes important
to examine possible explanations for these differences.
Toward that end, a questionnaire was mailed to female
patients who participated in these experiments in order
to investigate possible associations with reproductive physi-
ology. This questionnaire focused on age at menarche, regularity
of menstrual cycles, pregnancies, birth control, changes
in taste and smell, and interest in sex. Questionnaires
were mailed to the 23 female patients who participated in
the present study; 10 completed questionnaires were returned.
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Although the number of respondents was relatively small,
a number of interesting observations were made. The subgroup
of female patients who displayed a rebound in DMS recognition
had an earlier onset of menarche (13.3 vs 15.8 years of
age, respectively) and had more regular menstrual cycles.
Although the two groups of female patients had nearly identical
group means for the question dealing with interest in sex,
the group of female patients who displayed a rebound in
DMS recognition were reported to be either always interested
(3 repondents) or never interested in sex (3 respondents).
The other group of female patients were uniformly rated
as occasionally interested (4 respondents). Furthermore,
for the female patients who displayed a rebound in DMS recog-
nition, all 3 respondents who reported no interest in sex
also reported changes in taste and smell. Given the extensive
projections of the LC to the olfactory bulb (Shipley, Halloran,
and De La Torre, 1985), these preliminary findings are of
interest. Further studies of reproductive physiology in
female patients may provide a clue to the etiology of AD.
In Experiment 3, anomalous performance on either the
picture-recognition test or on the attentional focusing
test was associated with reduced levels of MHPG in patients
with AD. In Experiment 4, patients who displayed a rebound
in DMS performance responded differently to the administration
of the noradrenergic agonist, clonidine, than did patients
who did not display a rebound. If it is assumed that LC
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degeneration was associated with reduced levels of brain
NE, and that reductions in brain NE result in up-regulation
of postsynaptic noradrenergic receptors, then clonidine
administration would be expected to affect test performance
differentially in the two groups of patients. The results
of Experiment 4 thus provide pharmacological support of
the hypothesis that neuropsychological tests can identify
distinct groups of patients with AD. The hypothesis that
NE plays a role in human selective attention is also supported
by the present series of experiments.
The two subgroups of patients were similar in regard
to severity of dementia (Table 20). Because the amount
of additional study time for AD patients in the learning
phase was determined by BDS scores, there were also no signi-
ficant differences between the subgroups in regard to study
time (t(19) = .89, > .3). Thus, neither severity of dementia
or amount of study time can account for the differences
in performance between the two subgroups of patients.
The hypotheses that developed from these experiments
have important implications for future investigations.
The fact that behavioral tests can identify subgroups of
patients provides investigators with a tool to study the
longitudinal course of AD in different behavioral subgroups
as well as the means to typew patients in order to tailor
pharmacologic treatment. The delineation of subgroups of
patients is likely to provide clues to the etiology of AD.
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In addition, the results of these experiments suggest that
studies of sex-differences in patients with AD may yield
clues to the etiology of AD.
The hypothesis that reductions in brain NE secondary
to LC degeneration result in deficits in selective attention
can be further tested in the following ways: (1) study patients
with Parkinson's disease, in which LC degeneration is also
known to occur; or, (2) carefully document neuropsychological
deficits in the living patient and attempt to correlate
these deficits withneuropathologyat autopsy. These experiments
will help to define the role of the LC and NE in human cognition
and begin' to bridge the gap between clinical findings and
studies using experimental animals.
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Data for
1
Patients From Experiment 1
picture-recognition
10min 24hrs 72hrs
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95.0
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86.6
90.0
73.3
90.0
70.0
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66.6
55.0
50.0
95.0
focusing
2UE 3UE
-12
233
64
0
-152
29
CD
-58
-45
77
431
65
106
80
-160
-102
21
CD
-131
-54
143
370
CSF metabolites
MHPG 5HIAA HVA
8.3
13.1
6.9
5.7
4.1
5.3
7.7
9.9
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8 0 11.5
168 -151 11.7
-169 -138 6.2
12.6
-28 -25 5.6
52 144 8.1
574 391
...... - 6.3
262 262 10.3
129
id
T.M.
G.S.
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sex
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date
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Appendix 2
Data for Patients From Experiment
picture-recognition
id sex date 10min 24hrs 72hrs
focusing
2UE 3UE
CSF metabolites
MHPG SHIAA HVA
M.C. F 3/84 100.0 95.0 95.0
100.0 100.0 90.0
A.S. F 6/84 75.0 75.0 55.0
85.0 55.0 65.0
J.A. F 7/84 100.0 100.0 90.0
100.0 80.0 85.0
L.M. M 8/84 100.0 95.0 95.0
100.0 97.5 95.0
M.W. F 10/84 80.0 60.0 60.0
80.0 60.0 80.0
C.G. M 10/84 90.0 85.0 65.0
60.0 55.0 55.0
31 45 9.4 26.8 51.4
87 2 7.9 13.2 31.5
11 7
57 77
23 -34
-40 126
K.G. M 1/85 75.0 65.0 50.0
70.0 50.0 50.0
J.L. M 9/85 90.0 75.0 65.0
85.0 60.0 75.0
J.B. F 7/85 90.0 70.0 50.0
80.0 60.0 65.0
M.K. F 9/85 85.0 70.0
70.0 70.0
A.F. F 4/84 100.0 80.0 85.0
95.0 60.0 65.0
P.H. F 5/84 100.0 80.0 95.0
85.0 95.0 70.0
D.S. F 5/84 100.0 85.0 100.0
100.0 95.0 95.0
H.C. F 5/84 65.0 85.0 65.0
90.0 55.0 85.0
111 -462
-17 77
-28 -25
11 -14
71 -77
8.3 6.4
5.1 23.2 35.2
-101 -115
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10.0
Ill { i
-- --- 'i
K.W. M 7/84 100.0 95.0 100.0
100.0 100.0 85.0
M.C F 9/84 90.0 55.0 75.0
60.0 65.0 60.0
E.M. M 11/84 85.0 70.0 80.0
90.0 80.0 60.0
B.L. F 1/85 70.0 50.0 80.0
70.0 80.0 55.0
R.K. M 6/85 60.0 75.0 75.0
75.0 70.0 75.0
M.S. F 3/84 60.0 80.0 70.0
70.0 70.0 50.0
-74 -29 ---
CD CD 4.1 8.2
131
3 -15
-119 30
8 -27
-35 -64
11.3
Appendix 3
Test Data for Subject R.V. in Experiment 4
Best dose = .mg (6/8 tests)
Rebound
Baseline Best Dose
Rabbitt sorting
SRT (peripheral)
SRT (central)
CPT
Stroop color naming
Reading
Naming
Mixed
Picture-recognition
10 min DMS
10 min DNMS
24 hrs DMS
24 hrs DNMS
Naming to definition
Boston Naming
Word-list learning
Category fluency
-50 msec
456 msec
56
50
13
85
85
55
75
19
39
25
28
132
Test Washout
-5 -80
421 481
94
44
21
*71
48
20
75
55
70
70
75
70
65
55
21 20
39 40
50 48
34 36
L'' --
Appendix 4
Test Data for Subject L.E. in ExPeriment 4
Best dose = .lmg (4/8 tests)
Rebound
Baseline Best Dose
Rabbitt sorting
SRT (peripheral)
SRT (central)
CPT
Stroop color naming
Reading
Naming
Mixed
Picture-recognition
10 min DMS
10 min DNMS
24 hrs DMS
24 hrs DNMS
Naming to definition
Boston Naming
Word-list learning
Category fluency
Test Washout
-77msec
651msec
CD -15
CD 558
50
8
0
45
4
1
53
6
0
75
55
60
55
45
50
45
40
50
70
8
70
60
12
21
11
26
10
26
10
4
21
6 10
133
' ---- "-
Appendix 5
Test Data for Subject J.B. in Experiment 4
Best dose = .lmg (4/9 tests)
Rebound
Baseline Best Dose
Rabbitt sorting
SRT (peripheral)
SRT (central)
CPT
11,288msec
238msec
-175msec
723msec
Stroop color naming
Reading
Naming
Mixed
63
23
5
Picture-recognition
10 min DMS
10 min DNMS
24 hrs DMS
24 hrs DNMS
Naming to definition
Boston Naming
Word-list learning
Category fluency
90
80
70
60
10
17
34
14
134
Test Washout
4647
249
-221
CD
-140
264
CD
51
20
7
56
* 16
3
65
70
55
60
65
40
75
65
10 10
16 15
35 39
12 11
-- ------ ---- - - -- - ----
Appendix 6
Test Data for Subject J.A. in ExPeriment 4
Best dose = .lmg (3/10 tests)
Normal
Baseline Best Dose
Rabbitt sorting
SRT (peripheral)
SRT (central)
CPT (simple)
2449msec
-86msec
16msec
534msec
Stroop color naming
Reading
Naming
Mixed
55
33
1
Picture-recognition
10 min DMS
10 min DNMS
24 hrs DMS
24 hrs DNMS
Naming to definition
Boston Naming
Word-list learning
Category fluency
100
85
100
80
12
27
48
16
135
Test Washout
1253 1189
7 37
8 14
581 516
58
36
3
49
31
4
90
70
85
70
15 15
27 28
54 64
16 13
'" -" - --
Appendix 7
Test Data for Subject M.K. in Experiment 4
Best dose = .05mg (3/6 tests)
Normal
Baseline Best Dose
Rabbitt sorting
SRT (peripheral)
SRT (central)
CPT (simple)
Stroop color naming
Reading
Naming
Mixed
Picture-recognition
10 min DMS
10 min DNMS
24 hrs DMS
24 hrs DNMS
Naming to definition
Boston Naming
Word-list learning
Category fluency
1163msec
30msec
210msec
383msec
90
51
24
85
70
70
70
20
35
60
39
136
Test Washout
795
5
72 67
468 430
100
60
35
103
60
22
50
80
22 23
39
47 40
__ e, _ _ ..- I- I- __
~~~~~~~~~~~~~__
Appendix 8
Test Data for Subject L.N. in Experiment 4
Best dose = .05mg (5/10 tests)
Normal
Baseline Best Dose
Rabbitt sorting
SRT (peripheral)
SRT (central)
CPT (simple)
1106msec
-12msec
15msec
534msec
Stroop color naming
Reading
Naming
Mixed
70
22
13
Picture-recognition
10 min DMS
10 min DNMS
24 hrs DMS
24 hrs DNMS
Naming to definition
Boston Naming
Word-list learning
Category fluency
100
100
65
80
21
23
78
39
137
Test Washout
825 833
-87 -75
-37 123
560 600
45
30
25
54
31
19
100
100
95
85
22 22
29 27
73 78
48 47
''
